mseokt的个人主页 - 老虎社区

mseokt

暂无个人介绍

IP属地：未知

12关注

13粉丝

0主题

0勋章

2021-12-06

It's December vacation drop time

抱歉，原内容已删除

2021-12-05

Maybe it's the holiday season. Stocks may he going south for vacation

抱歉，原内容已删除

2021-12-05

Marvell- superhero company? Like Nvidia, need to monitor

Marvell will be 'in the same camp' as AMD, Nvidia after 'one of the best' semiconductor earnings calls

2021-11-12

Easy treatment for Covid-19 👍

抱歉，原内容已删除

2021-11-12

Hmmm looks like can consider Exelixis

抱歉，原内容已删除

2021-11-08

Doesn't seem positive sign

Twitter Has Spoken: Musk Should Sell $21 Billion Tesla Stake

2021-11-08

Look like an exciting week

抱歉，原内容已删除

2021-11-05

Hopefully the pill is effective

Britain approves Merck's Covid-19 pill in world first

2021-11-05

AIG coming back strongly

AIG profit beats Wall St estimates on general insurance boost

2021-10-27

Seem like a confident stock.

抱歉，原内容已删除

2021-10-14

Not many have courage to buy at dying moments

抱歉，原内容已删除

2021-10-14

Good to monitor

UiPath Announces Partnership with Snowflake to Power Robotic Process Automation Analytics in the Cloud

2021-10-14

Selling mode??

FDA Staff Makes No Recommendation on J&J Covid Shot Booster

2021-10-11

Hopefully an effective drug for treating Covid.

AstraZeneca Antibody Drug Effective at Treating Mild Covid in Trial

2021-10-08

Looks like mostly going up.

Toplines Before US Market Open on Friday

2021-10-04

Flying may be open. Unless real urgent and necessary, would be on wait-see mentality as still unsure if any sudden closure or quarantine measure.

抱歉，原内容已删除

2021-10-04

With covid situation, likely to watch programmes at uome. So Netflix should be staying stable

Netflix Stock Is Making Record Highs; Could It Keep Going Higher?

2021-09-30

Positive or negative? Hopeful

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3577447162748311,"uuid":"3577447162748311","gmtCreate":1614353700812,"gmtModify":1614353700812,"name":"mseokt","pinyin":"mseokt","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":13,"headSize":12,"tweetSize":85,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":606007577,"gmtCreate":1638798648742,"gmtModify":1638799923736,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"It's December vacation drop time","listText":"It's December vacation drop time","text":"It's December vacation drop time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606007577","repostId":"1191091006","repostType":4,"isVote":1,"tweetType":1,"viewCount":1069,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608167693,"gmtCreate":1638668134727,"gmtModify":1638668134860,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Maybe it's the holiday season. Stocks may he going south for vacation","listText":"Maybe it's the holiday season. Stocks may he going south for vacation","text":"Maybe it's the holiday season. Stocks may he going south for vacation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608167693","repostId":"1115344844","repostType":4,"isVote":1,"tweetType":1,"viewCount":491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608164742,"gmtCreate":1638668011612,"gmtModify":1638668011716,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Marvell- superhero company? Like Nvidia, need to monitor&nbsp;","listText":"Marvell- superhero company? Like Nvidia, need to monitor&nbsp;","text":"Marvell- superhero company? Like Nvidia, need to monitor","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608164742","repostId":"2188787815","repostType":4,"repost":{"id":"2188787815","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638583020,"share":"https://www.laohu8.com/m/news/2188787815?lang=&edition=full","pubTime":"2021-12-04 09:57","market":"us","language":"en","title":"Marvell will be 'in the same camp' as AMD, Nvidia after 'one of the best' semiconductor earnings calls","url":"https://stock-news.laohu8.com/highlight/detail?id=2188787815","media":"Dow Jones","summary":"Stock jumps more than 17%, its best day since 2008, as analysts describe chip maker's earnings as 'w","content":"<p>Stock jumps more than 17%, its best day since 2008, as analysts describe chip maker's earnings as 'watershed quarter'</p>\n<p>Shares of Marvell Technology Inc. experienced their best trading day in 13 years after an earnings report that led analysts to predict the chip maker's ascension into the top tier of hot semiconductor stocks.</p>\n<p>Marvell shares <a href=\"https://laohu8.com/S/MRVL\">$(MRVL)$</a> increased 17.7% Friday following the company's fiscal third-quarter earnings report, which saw Marvell top expectations for its latest quarter, issue an upbeat forecast for the current period, and offer encouraging longer-term commentary. The stock posted its largest single-day percentage gain since Dec. 3, 2008, when it rose 20.4%.</p>\n<p>Chief Financial Officer Jean Hu said on the earnings call late Thursday that she expects \"continued strong demand across our end markets and improvement in supply to drive our top line revenue growth above 30% in fiscal 2023.\" That projection generated enthusiasm, as did Marvell's January-quarter revenue forecast that implied upwards of 60% growth.</p>\n<p>The company's earnings call could have been \"one of the best (if not the best) semi conf[erence] calls I have listened to in quite some time,\" wrote Mizuho desk-based analyst Jordan Klein in a note affiliated with Mizuho's sales operations and not its research team. \"In fact, it was a GAME-CHANGER for investors and in my view squarely positions Marvell as a best-in-class GROWTH SEMI into CY22,\" he continued.</p>\n<p>Marvell \"will be in the same camp now\" as Advanced Micro Devices Inc. <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a> and Nvidia Corp. <a href=\"https://laohu8.com/S/NVDA\">$(NVDA)$</a>, he argued, amid the company's cheery growth projections and likely expectations among the bull camp for $4 a share in annual earnings power within a few years. The company has a \"clear line of sight given a backlog full of design wins that has basically locked in that growth rate\" on the revenue line, he said in his note.</p>\n<p>The current FactSet EPS consensus is $1.54 for the current fiscal year, and is $2.20 for next year.</p>\n<p>Klein wasn't alone in likening Marvell to a red-hot chip stock. \"Marvell just pulled an 'Nvidia' on the Street last night, with an unambiguous beat and raise and taking FY23 sales growth to over 30%,\" Rosenblatt Securities analyst Hans Mosesmann wrote.</p>\n<p>Marvell's report sparked at least one upgrade from a research analyst: Cowen &amp; Co.'s Karl Ackerman, who lifted his rating on Marvell's stock to outperform from market perform.</p>\n<p>\"It's hard to argue this was anything but a watershed quarter with a triad of better results, better guidance, and an expanding design pipeline that anchors a new F23 guide,\" Ackerman wrote.</p>\n<p>Ackerman cheered Marvell's recent evolution, anchored by \"portfolio-optimization\" progress that has made the company increasingly competitive, in his view.</p>\n<p>\"Marvell has transformed itself from being a fast-follower to a market leader of providing semi-custom, integrated ICs on leading-edge silicon that address bandwidth friction existing in today's networks,\" he wrote, while increasing his price target to $100 from $60.</p>\n<p>The report served as validation for those who had already taken bullish views on the stock and are now bringing their expectations higher. \"Taking a step back, we have been highlighting Marvell as one of the best growth stories in semis, and to this end they are clearly not disappointing,\" Evercore ISI analyst C.J. Muse wrote.</p>\n<p>Muse now sees \"a clear path to a $3.25+ earnings stretch goal in FY24,\" whereas the consensus was for $2.43 a share, he said. \"Looking out further, we believe that the $4.00 bogey we have been discussing by CY25 is now likely conservative -- with earnings likely tracking closer to $4.25+ when all is said and done (at a minimum),\" Muse continued, while boosting his price target to $105 from $72 and keeping an outperform rating.</p>\n<p>Marvell shares have rocketed 75% so far this year, while Nvidia shares have soared 134%, AMD's stock has rallied 56% and the S&amp;P 500 has risen 20%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marvell will be 'in the same camp' as AMD, Nvidia after 'one of the best' semiconductor earnings calls</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarvell will be 'in the same camp' as AMD, Nvidia after 'one of the best' semiconductor earnings calls\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-04 09:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stock jumps more than 17%, its best day since 2008, as analysts describe chip maker's earnings as 'watershed quarter'</p>\n<p>Shares of Marvell Technology Inc. experienced their best trading day in 13 years after an earnings report that led analysts to predict the chip maker's ascension into the top tier of hot semiconductor stocks.</p>\n<p>Marvell shares <a href=\"https://laohu8.com/S/MRVL\">$(MRVL)$</a> increased 17.7% Friday following the company's fiscal third-quarter earnings report, which saw Marvell top expectations for its latest quarter, issue an upbeat forecast for the current period, and offer encouraging longer-term commentary. The stock posted its largest single-day percentage gain since Dec. 3, 2008, when it rose 20.4%.</p>\n<p>Chief Financial Officer Jean Hu said on the earnings call late Thursday that she expects \"continued strong demand across our end markets and improvement in supply to drive our top line revenue growth above 30% in fiscal 2023.\" That projection generated enthusiasm, as did Marvell's January-quarter revenue forecast that implied upwards of 60% growth.</p>\n<p>The company's earnings call could have been \"one of the best (if not the best) semi conf[erence] calls I have listened to in quite some time,\" wrote Mizuho desk-based analyst Jordan Klein in a note affiliated with Mizuho's sales operations and not its research team. \"In fact, it was a GAME-CHANGER for investors and in my view squarely positions Marvell as a best-in-class GROWTH SEMI into CY22,\" he continued.</p>\n<p>Marvell \"will be in the same camp now\" as Advanced Micro Devices Inc. <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a> and Nvidia Corp. <a href=\"https://laohu8.com/S/NVDA\">$(NVDA)$</a>, he argued, amid the company's cheery growth projections and likely expectations among the bull camp for $4 a share in annual earnings power within a few years. The company has a \"clear line of sight given a backlog full of design wins that has basically locked in that growth rate\" on the revenue line, he said in his note.</p>\n<p>The current FactSet EPS consensus is $1.54 for the current fiscal year, and is $2.20 for next year.</p>\n<p>Klein wasn't alone in likening Marvell to a red-hot chip stock. \"Marvell just pulled an 'Nvidia' on the Street last night, with an unambiguous beat and raise and taking FY23 sales growth to over 30%,\" Rosenblatt Securities analyst Hans Mosesmann wrote.</p>\n<p>Marvell's report sparked at least one upgrade from a research analyst: Cowen &amp; Co.'s Karl Ackerman, who lifted his rating on Marvell's stock to outperform from market perform.</p>\n<p>\"It's hard to argue this was anything but a watershed quarter with a triad of better results, better guidance, and an expanding design pipeline that anchors a new F23 guide,\" Ackerman wrote.</p>\n<p>Ackerman cheered Marvell's recent evolution, anchored by \"portfolio-optimization\" progress that has made the company increasingly competitive, in his view.</p>\n<p>\"Marvell has transformed itself from being a fast-follower to a market leader of providing semi-custom, integrated ICs on leading-edge silicon that address bandwidth friction existing in today's networks,\" he wrote, while increasing his price target to $100 from $60.</p>\n<p>The report served as validation for those who had already taken bullish views on the stock and are now bringing their expectations higher. \"Taking a step back, we have been highlighting Marvell as one of the best growth stories in semis, and to this end they are clearly not disappointing,\" Evercore ISI analyst C.J. Muse wrote.</p>\n<p>Muse now sees \"a clear path to a $3.25+ earnings stretch goal in FY24,\" whereas the consensus was for $2.43 a share, he said. \"Looking out further, we believe that the $4.00 bogey we have been discussing by CY25 is now likely conservative -- with earnings likely tracking closer to $4.25+ when all is said and done (at a minimum),\" Muse continued, while boosting his price target to $105 from $72 and keeping an outperform rating.</p>\n<p>Marvell shares have rocketed 75% so far this year, while Nvidia shares have soared 134%, AMD's stock has rallied 56% and the S&amp;P 500 has risen 20%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","MRVL":"迈威尔科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188787815","content_text":"Stock jumps more than 17%, its best day since 2008, as analysts describe chip maker's earnings as 'watershed quarter'\nShares of Marvell Technology Inc. experienced their best trading day in 13 years after an earnings report that led analysts to predict the chip maker's ascension into the top tier of hot semiconductor stocks.\nMarvell shares $(MRVL)$ increased 17.7% Friday following the company's fiscal third-quarter earnings report, which saw Marvell top expectations for its latest quarter, issue an upbeat forecast for the current period, and offer encouraging longer-term commentary. The stock posted its largest single-day percentage gain since Dec. 3, 2008, when it rose 20.4%.\nChief Financial Officer Jean Hu said on the earnings call late Thursday that she expects \"continued strong demand across our end markets and improvement in supply to drive our top line revenue growth above 30% in fiscal 2023.\" That projection generated enthusiasm, as did Marvell's January-quarter revenue forecast that implied upwards of 60% growth.\nThe company's earnings call could have been \"one of the best (if not the best) semi conf[erence] calls I have listened to in quite some time,\" wrote Mizuho desk-based analyst Jordan Klein in a note affiliated with Mizuho's sales operations and not its research team. \"In fact, it was a GAME-CHANGER for investors and in my view squarely positions Marvell as a best-in-class GROWTH SEMI into CY22,\" he continued.\nMarvell \"will be in the same camp now\" as Advanced Micro Devices Inc. $(AMD)$ and Nvidia Corp. $(NVDA)$, he argued, amid the company's cheery growth projections and likely expectations among the bull camp for $4 a share in annual earnings power within a few years. The company has a \"clear line of sight given a backlog full of design wins that has basically locked in that growth rate\" on the revenue line, he said in his note.\nThe current FactSet EPS consensus is $1.54 for the current fiscal year, and is $2.20 for next year.\nKlein wasn't alone in likening Marvell to a red-hot chip stock. \"Marvell just pulled an 'Nvidia' on the Street last night, with an unambiguous beat and raise and taking FY23 sales growth to over 30%,\" Rosenblatt Securities analyst Hans Mosesmann wrote.\nMarvell's report sparked at least one upgrade from a research analyst: Cowen & Co.'s Karl Ackerman, who lifted his rating on Marvell's stock to outperform from market perform.\n\"It's hard to argue this was anything but a watershed quarter with a triad of better results, better guidance, and an expanding design pipeline that anchors a new F23 guide,\" Ackerman wrote.\nAckerman cheered Marvell's recent evolution, anchored by \"portfolio-optimization\" progress that has made the company increasingly competitive, in his view.\n\"Marvell has transformed itself from being a fast-follower to a market leader of providing semi-custom, integrated ICs on leading-edge silicon that address bandwidth friction existing in today's networks,\" he wrote, while increasing his price target to $100 from $60.\nThe report served as validation for those who had already taken bullish views on the stock and are now bringing their expectations higher. \"Taking a step back, we have been highlighting Marvell as one of the best growth stories in semis, and to this end they are clearly not disappointing,\" Evercore ISI analyst C.J. Muse wrote.\nMuse now sees \"a clear path to a $3.25+ earnings stretch goal in FY24,\" whereas the consensus was for $2.43 a share, he said. \"Looking out further, we believe that the $4.00 bogey we have been discussing by CY25 is now likely conservative -- with earnings likely tracking closer to $4.25+ when all is said and done (at a minimum),\" Muse continued, while boosting his price target to $105 from $72 and keeping an outperform rating.\nMarvell shares have rocketed 75% so far this year, while Nvidia shares have soared 134%, AMD's stock has rallied 56% and the S&P 500 has risen 20%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1013,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879250947,"gmtCreate":1636729609420,"gmtModify":1636732552491,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Easy treatment for Covid-19 👍","listText":"Easy treatment for Covid-19 👍","text":"Easy treatment for Covid-19 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879250947","repostId":"1148576456","repostType":2,"isVote":1,"tweetType":1,"viewCount":661,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879203385,"gmtCreate":1636725208738,"gmtModify":1636725274754,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hmmm looks like can consider Exelixis&nbsp;","listText":"Hmmm looks like can consider Exelixis&nbsp;","text":"Hmmm looks like can consider Exelixis","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879203385","repostId":"2182094779","repostType":4,"isVote":1,"tweetType":1,"viewCount":942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845641636,"gmtCreate":1636336761554,"gmtModify":1636337088742,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Doesn't seem positive sign","listText":"Doesn't seem positive sign","text":"Doesn't seem positive sign","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845641636","repostId":"2181233137","repostType":4,"repost":{"id":"2181233137","pubTimestamp":1636333076,"share":"https://www.laohu8.com/m/news/2181233137?lang=&edition=full","pubTime":"2021-11-08 08:57","market":"us","language":"en","title":"Twitter Has Spoken: Musk Should Sell $21 Billion Tesla Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2181233137","media":"Bloomberg","summary":"(Bloomberg) -- Elon Musk’s social media followers have spoken: The Tesla Inc. chief should sell 10% ","content":"<p>(Bloomberg) -- Elon Musk’s social media followers have spoken: The Tesla Inc. chief should sell 10% of his stake in the electric-car maker.</p>\n<p>A majority of 3.5 million <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users said they’d support the move in a poll that Musk launched Saturday when he floated the idea of selling the stock, which is valued at about $21 billion based on 170.5 million Tesla shares he holds. The poll closed shortly after 2:15 p.m. Sunday in New York, with about 58% of respondents backing the idea of the sale.</p>\n<p>“I was prepared to accept either outcome,” Musk said in a tweet after the poll closed.</p>\n<p>The crowd-sourcing exercise is the latest example of Musk’s long history of using Twitter and his legions of fans on the platform to stoke interest in his company, sometimes pushing the envelope with tongue-in-cheek tweets. The world’s richest person proposed the move in a tweet citing recent discussions about the ultra-wealthy hoarding unrealized gains to avoid paying taxes. Musk doesn’t take a salary, but has to pay taxes on any stock options that he exercises.</p>\n<p>While large sales by insiders are often seen as a negative signal, a sale of this size won’t alter Tesla’s story in a meaningful way, said Dan Ives, an analyst at Wedbush Securities. Demand remains high for Tesla shares among both institutional and retail investors, he said. The unorthodox step of getting buy-in from fans and investors via a poll may also ease any concerns.</p>\n<p>“Selling 10% is probably going to add 1.5% to 2% to the float, so it doesn’t really significantly move the needle,” Ives said in a phone interview. “I do believe that him doing it in this way definitely would soften the blow and would help the perception as well.”</p>\n<p>Read more: Musk wants to use his money for Mars venture</p>\n<p>The automaker’s stock has soared 73% this year, giving it a valuation of $1.2 trillion as of Nov. 5. The number of shares that Musk -- its chief executive officer and largest shareholder -- could be set to offload is equivalent to 80% of Tesla’s average daily trading volume in the past three months. The amount of stock he may potentially sell would be even greater if his options are included.</p>\n<p>Tesla’s stock closed at $1,222.09 on Nov. 5 and won’t officially begin trading again until the early morning hours of Monday in the U.S. But, in Sunday trading on FTX, a cryptocurrency version of Tesla’s shares recently fetched $1,138.95 -- 6.8% lower than the Friday close -- suggesting Musk’s tweeting could cause the real thing to fall when Wall Street wakes up.</p>\n<p>Personal Fortune</p>\n<p>Musk’s fortune stands at $338 billion, according to the Bloomberg Billionaires Index. About <a href=\"https://laohu8.com/S/AONE.U\">one</a>-quarter of that consists of Tesla stock options that he’s free to exercise at any time. The securities come from two big awards he received in 2012 and 2018. The older contracts expire in August next year.</p>\n<p>If he exercised all of the options now and immediately sold the shares, they would net him $95.9 billion before taxes.</p>\n<p>Musk may be signaling that he wants liquidity beyond the cash he’s secured by borrowing against his holdings in the EV maker. Last week he suggested he’d sell some stock if the UN could prove $6 billion could help alleviate world hunger. For years, Musk has said he would be the last to ever sell stock, and has often added to his position when Tesla has raised money from Wall Street so that his stake is not diluted.</p>\n<p>Tax Situation</p>\n<p>Musk moved to Texas, which has no state personal income tax, in late 2020. But as Tesla’s market value has skyrocketed and his personal wealth has ballooned, Musk has become a symbol of rising inequality -- something he appears to be sensitive to. He was among the billionaires mentioned in a Pro Publica investigation of how the ultra rich avoid paying taxes, and has become a target of members of Congress who are pushing a billionaires tax.</p>\n<p>“Whether or not the world’s wealthiest man pays any taxes at all shouldn’t depend on the results of a Twitter poll,” U.S. Senator Ron Wyden, an Oregon Democrat, wrote in a tweet Saturday. “It’s time for the Billionaires Income Tax.”</p>\n<p>On his way to becoming the world’s richest person, Musk has made millionaires -- and even at least one billionaire -- among some of his fans, employees and other investors. Among them is Leo KoGuan, a Singapore-based retail investor and business owner who used his already considerable wealth to amass more than $7 billion in Tesla shares.</p>\n<p>Count KoGuan among those Twitter followers who say it’s time for Musk to take some money out of the automaker, even if it is just to use it in Musk’s other ventures exploring space and neural networks. “Politically and from tax point of view and given that Elon is poor in cash, he has no choice but to sell his stakes to pay tax and to be cash-rich,” KoGuan posted on Nov. 6.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Twitter Has Spoken: Musk Should Sell $21 Billion Tesla Stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwitter Has Spoken: Musk Should Sell $21 Billion Tesla Stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-08 08:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/twitter-spoken-musk-sell-21-191936098.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Elon Musk’s social media followers have spoken: The Tesla Inc. chief should sell 10% of his stake in the electric-car maker.\nA majority of 3.5 million Twitter users said they’d support ...</p>\n\n<a href=\"https://finance.yahoo.com/news/twitter-spoken-musk-sell-21-191936098.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/d205ca2e382136d92a6cf58671c6e098","relate_stocks":{"TWTR":"Twitter","TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/twitter-spoken-musk-sell-21-191936098.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2181233137","content_text":"(Bloomberg) -- Elon Musk’s social media followers have spoken: The Tesla Inc. chief should sell 10% of his stake in the electric-car maker.\nA majority of 3.5 million Twitter users said they’d support the move in a poll that Musk launched Saturday when he floated the idea of selling the stock, which is valued at about $21 billion based on 170.5 million Tesla shares he holds. The poll closed shortly after 2:15 p.m. Sunday in New York, with about 58% of respondents backing the idea of the sale.\n“I was prepared to accept either outcome,” Musk said in a tweet after the poll closed.\nThe crowd-sourcing exercise is the latest example of Musk’s long history of using Twitter and his legions of fans on the platform to stoke interest in his company, sometimes pushing the envelope with tongue-in-cheek tweets. The world’s richest person proposed the move in a tweet citing recent discussions about the ultra-wealthy hoarding unrealized gains to avoid paying taxes. Musk doesn’t take a salary, but has to pay taxes on any stock options that he exercises.\nWhile large sales by insiders are often seen as a negative signal, a sale of this size won’t alter Tesla’s story in a meaningful way, said Dan Ives, an analyst at Wedbush Securities. Demand remains high for Tesla shares among both institutional and retail investors, he said. The unorthodox step of getting buy-in from fans and investors via a poll may also ease any concerns.\n“Selling 10% is probably going to add 1.5% to 2% to the float, so it doesn’t really significantly move the needle,” Ives said in a phone interview. “I do believe that him doing it in this way definitely would soften the blow and would help the perception as well.”\nRead more: Musk wants to use his money for Mars venture\nThe automaker’s stock has soared 73% this year, giving it a valuation of $1.2 trillion as of Nov. 5. The number of shares that Musk -- its chief executive officer and largest shareholder -- could be set to offload is equivalent to 80% of Tesla’s average daily trading volume in the past three months. The amount of stock he may potentially sell would be even greater if his options are included.\nTesla’s stock closed at $1,222.09 on Nov. 5 and won’t officially begin trading again until the early morning hours of Monday in the U.S. But, in Sunday trading on FTX, a cryptocurrency version of Tesla’s shares recently fetched $1,138.95 -- 6.8% lower than the Friday close -- suggesting Musk’s tweeting could cause the real thing to fall when Wall Street wakes up.\nPersonal Fortune\nMusk’s fortune stands at $338 billion, according to the Bloomberg Billionaires Index. About one-quarter of that consists of Tesla stock options that he’s free to exercise at any time. The securities come from two big awards he received in 2012 and 2018. The older contracts expire in August next year.\nIf he exercised all of the options now and immediately sold the shares, they would net him $95.9 billion before taxes.\nMusk may be signaling that he wants liquidity beyond the cash he’s secured by borrowing against his holdings in the EV maker. Last week he suggested he’d sell some stock if the UN could prove $6 billion could help alleviate world hunger. For years, Musk has said he would be the last to ever sell stock, and has often added to his position when Tesla has raised money from Wall Street so that his stake is not diluted.\nTax Situation\nMusk moved to Texas, which has no state personal income tax, in late 2020. But as Tesla’s market value has skyrocketed and his personal wealth has ballooned, Musk has become a symbol of rising inequality -- something he appears to be sensitive to. He was among the billionaires mentioned in a Pro Publica investigation of how the ultra rich avoid paying taxes, and has become a target of members of Congress who are pushing a billionaires tax.\n“Whether or not the world’s wealthiest man pays any taxes at all shouldn’t depend on the results of a Twitter poll,” U.S. Senator Ron Wyden, an Oregon Democrat, wrote in a tweet Saturday. “It’s time for the Billionaires Income Tax.”\nOn his way to becoming the world’s richest person, Musk has made millionaires -- and even at least one billionaire -- among some of his fans, employees and other investors. Among them is Leo KoGuan, a Singapore-based retail investor and business owner who used his already considerable wealth to amass more than $7 billion in Tesla shares.\nCount KoGuan among those Twitter followers who say it’s time for Musk to take some money out of the automaker, even if it is just to use it in Musk’s other ventures exploring space and neural networks. “Politically and from tax point of view and given that Elon is poor in cash, he has no choice but to sell his stakes to pay tax and to be cash-rich,” KoGuan posted on Nov. 6.","news_type":1},"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845643010,"gmtCreate":1636336663260,"gmtModify":1636337071848,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Look like an exciting week","listText":"Look like an exciting week","text":"Look like an exciting week","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845643010","repostId":"2181284457","repostType":4,"isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846682292,"gmtCreate":1636078065172,"gmtModify":1636079495059,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hopefully the pill is effective&nbsp;","listText":"Hopefully the pill is effective&nbsp;","text":"Hopefully the pill is effective","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846682292","repostId":"2180795475","repostType":4,"repost":{"id":"2180795475","pubTimestamp":1636076165,"share":"https://www.laohu8.com/m/news/2180795475?lang=&edition=full","pubTime":"2021-11-05 09:36","market":"us","language":"en","title":"Britain approves Merck's Covid-19 pill in world first","url":"https://stock-news.laohu8.com/highlight/detail?id=2180795475","media":"The Straits Times","summary":"Nov 4 (Reuters) - Britain on Thursday became the first country in the world to approve a potentially","content":"<div>\n<p>Nov 4 (Reuters) - Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by U.S.-based Merck & Co Inc(MRK.N)and ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/britain-approves-mercks-covid-19-pill-in-world-first\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Britain approves Merck's Covid-19 pill in world first</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBritain approves Merck's Covid-19 pill in world first\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 09:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/europe/britain-approves-mercks-covid-19-pill-in-world-first><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 4 (Reuters) - Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by U.S.-based Merck & Co Inc(MRK.N)and ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/britain-approves-mercks-covid-19-pill-in-world-first\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"http://www.straitstimes.com/world/europe/britain-approves-mercks-covid-19-pill-in-world-first","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180795475","content_text":"Nov 4 (Reuters) - Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by U.S.-based Merck & Co Inc(MRK.N)and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic.\nBritain's Medicines and Healthcare products Regulatory Agency (MHRA)recommended the drug, molnupiravir, for use in people with mild to moderate COVID-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease.\nIt will be administered as soon as possible following a positive COVID-19 test and within five days of the onset of symptoms, the regulator said, citing clinical data.\nThe green light is the first for an oral antiviral treatment for COVID-19 and the first for a COVID-19 drug that will be administered widely in the community. U.S. advisers will meet on Nov. 30 to review the drug's safety and efficacy data and vote on whether molnupiravir should be authorized.read more\nThe pill, which will be branded as Lagevrio in Britain, is designed to introduce errors into the genetic code of the coronavirus that causes COVID-19 and is taken twice a day for five days.\nDrugs in the same class as molnupiravir have been linked to birth defects in animal studies. Merck, known as MSD outside of the United States and Canada, has said animal testing shows that molnupiravir is safe, but the data have not yet been made public.\nTreatments to tackle the pandemic, which has killed more than 5.2 million people worldwide, have so far focused mainly on vaccines. Other options, including Gilead's(GILD.O)infused antiviral remdesivir and generic steroid dexamethasone, are generally only given after a patient has been hospitalised.\nMerck's Molnupiravir has been closely watched since data last month showed it could halve the chances of dying or being hospitalised for those most at risk of developing severe COVID-19 when given early in the illness.\nProfessor Stephen Powis, national medical director for the National Health Service (NHS) in England, said the drug would be administered to patients at higher risk of complications as Britain heads into one of the most challenging winters ever.\nA wider rollout will follow if it is clinically and cost effective in reducing hospitalisations and death, he added.\n\"We are now working across government and the NHS to urgently get this treatment to patients initially through a national study so we can collect more data on how antivirals work in a mostly vaccinated population,\" UK vaccines minister Maggie Throup told parliament.\nPRESSURES\nThe speedy approval in Britain, which was also the first Western country to approve a COVID-19 vaccine, comes as it struggles to tame soaring infections.\nBritain has about 40,000 daily cases of COVID-19, according to the latest seven-day average. That is second only to the roughly 74,000 a day in the United States, which has five times more people, and has fuelled criticism of the government's decision to abandon most pandemic-related restrictions\nData released on Wednesday night showed COVID-19 prevalence in England hit its highest level on record last month, led by a high number of cases in children and a surge in the south-west of the country.\nPressure is growing on the government to implement its \"Plan B\" aimed at protecting the NHS from unsustainable demands, involving mask mandates, vaccine passes and work-from-home orders.\nMany other big economies, including Germany, France and Israel, have either retained some basic COVID-19 measures like mask mandates or reintroduced them in response to rising cases.\nThe UK government has said its focus remains on administering vaccine boosters and inoculating 12- to 15-year-olds.\n\"With no compromises on quality, safety and effectiveness, the public can trust that the MHRA has conducted a robust and thorough assessment of the data (on molnupiravir),\" MHRA chief June Raine said in a statement.\nLast month, Britain agreed a deal with Merck tosecure480,000 courses of molnupiravir.\nProfessor Penny Ward, an independent pharmaceutical physician, welcomed the approval, but said the NHS needed to outline its plans for rollout and cautioned that supplies were likely to be tight given the strong global demand.\n\"Comments made by Mr Javid today suggest that it may be made available via a clinical trial, presumably to investigate its effectiveness in vaccinated patients with breakthrough infections, as the original study incorporated unvaccinated adults,\" she said.\nIf given to everyone becoming unwell, the nearly half a million courses would not last very long given the more than 40,000 current daily case rate, she said.\nTREATMENT RACE\nIn a separate statement, Merck said it expected to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.\nThe U.S.-based drugmaker's shares rose 2.1% to close at $90.54 on Thursday.\nPfizer(PFE.N)and Roche(ROG.S)are also racing to develop easy-to-administer antiviral pills for COVID-19.\nBoth Merck and Pfizer are studying their drugs in late-stage trials for preventing coronavirus infection.\nViral sequencing done so far has shown molnupiravir is effective against all variants of the coronavirus, Merck has said, including the more-infectious Delta, which is responsible for the worldwide surge in hospitalisations and deaths recently.\nWhile it is not yet clear when Merck will deliver doses to Britain, the company has said it is committed to providing timely access to its drug globally with plans for tiered pricing aligned with a country's ability to pay.\nMerck has licensed the drug to generic drugmakers for supply to low-income countries.\nAntibody cocktails like those from Regeneron(REGN.O)and Eli Lilly(LLY.N)have also been approved for non-hospitalised COVID-19 patients, but have to be given intravenously.","news_type":1},"isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846686643,"gmtCreate":1636077977968,"gmtModify":1636079490224,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"AIG coming back strongly&nbsp;","listText":"AIG coming back strongly&nbsp;","text":"AIG coming back strongly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846686643","repostId":"2181797266","repostType":4,"repost":{"id":"2181797266","pubTimestamp":1636076520,"share":"https://www.laohu8.com/m/news/2181797266?lang=&edition=full","pubTime":"2021-11-05 09:42","market":"us","language":"en","title":"AIG profit beats Wall St estimates on general insurance boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2181797266","media":"StreetInsider","summary":"(Reuters) - American International Group Inc exceeded market estimates for quarterly profit on Thurs","content":"<p>(Reuters) - American International Group Inc exceeded market estimates for quarterly profit on Thursday as its general insurance business faced fewer natural catastrophe and COVID-19 pandemic-related claims.</p>\n<p>The U.S. insurer posted an underwriting income of $20 million in its general insurance business in the third quarter, compared with a $423 million loss a year earlier.</p>\n<p>The business recorded catastrophe losses of $628 million, mainly from Hurricane Ida and floods in the United Kingdom and Europe. That compared with $790 million a year ago, which included $185 million of estimated COVID-19 losses.</p>\n<p>Global insurers last year faced a sharp rise in payouts related to the health crisis, but a wider availability of COVID-19 vaccines has eased the pressure.</p>\n<p>Adjusted after-tax income attributable to AIG's common shareholders rose to $837 million in the quarter to Sept. 30, from $708 million a year earlier.</p>\n<p>AIG earned 97 cents per share on an adjusted basis, beating analysts' estimates of 88 cents, according to Refinitiv.</p>\n<p>The company's general insurance accident year combined ratio - which excludes catastrophe losses - was 90.5 for the quarter, compared with 93.3 a year earlier.</p>\n<p>A ratio below 100 means the insurer earns more in premiums than it pays out in claims.</p>\n<p>Gross premiums written rose 13% to $8.3 billion in the general insurance business.</p>\n<p>AIG's life and retirement unit posted a 13% fall in adjusted pre-tax income to $877 million.</p>\n<p>The company said the planned initial public offering of the unit, in which Blackstone Group has bought a sizeable stake, was on track for 2022.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIG profit beats Wall St estimates on general insurance boost</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIG profit beats Wall St estimates on general insurance boost\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 09:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19163614><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - American International Group Inc exceeded market estimates for quarterly profit on Thursday as its general insurance business faced fewer natural catastrophe and COVID-19 pandemic-related ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19163614\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AIG":"美国国际集团"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19163614","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181797266","content_text":"(Reuters) - American International Group Inc exceeded market estimates for quarterly profit on Thursday as its general insurance business faced fewer natural catastrophe and COVID-19 pandemic-related claims.\nThe U.S. insurer posted an underwriting income of $20 million in its general insurance business in the third quarter, compared with a $423 million loss a year earlier.\nThe business recorded catastrophe losses of $628 million, mainly from Hurricane Ida and floods in the United Kingdom and Europe. That compared with $790 million a year ago, which included $185 million of estimated COVID-19 losses.\nGlobal insurers last year faced a sharp rise in payouts related to the health crisis, but a wider availability of COVID-19 vaccines has eased the pressure.\nAdjusted after-tax income attributable to AIG's common shareholders rose to $837 million in the quarter to Sept. 30, from $708 million a year earlier.\nAIG earned 97 cents per share on an adjusted basis, beating analysts' estimates of 88 cents, according to Refinitiv.\nThe company's general insurance accident year combined ratio - which excludes catastrophe losses - was 90.5 for the quarter, compared with 93.3 a year earlier.\nA ratio below 100 means the insurer earns more in premiums than it pays out in claims.\nGross premiums written rose 13% to $8.3 billion in the general insurance business.\nAIG's life and retirement unit posted a 13% fall in adjusted pre-tax income to $877 million.\nThe company said the planned initial public offering of the unit, in which Blackstone Group has bought a sizeable stake, was on track for 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855176855,"gmtCreate":1635346038695,"gmtModify":1635346149970,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Seem like a confident stock.&nbsp;","listText":"Seem like a confident stock.&nbsp;","text":"Seem like a confident stock.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/855176855","repostId":"1106140847","repostType":4,"isVote":1,"tweetType":1,"viewCount":693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825911544,"gmtCreate":1634188667408,"gmtModify":1634188667522,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Not many have courage to buy at dying moments","listText":"Not many have courage to buy at dying moments","text":"Not many have courage to buy at dying moments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/825911544","repostId":"1111412750","repostType":4,"isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825913447,"gmtCreate":1634188594828,"gmtModify":1634188594904,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good to monitor","listText":"Good to monitor","text":"Good to monitor","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825913447","repostId":"2175503591","repostType":4,"repost":{"id":"2175503591","pubTimestamp":1634183340,"share":"https://www.laohu8.com/m/news/2175503591?lang=&edition=full","pubTime":"2021-10-14 11:49","market":"us","language":"en","title":"UiPath Announces Partnership with Snowflake to Power Robotic Process Automation Analytics in the Cloud","url":"https://stock-news.laohu8.com/highlight/detail?id=2175503591","media":"Business Wire","summary":"Enables customers to perform long-term historical analysis to scale their automation journeys to the","content":"<p><i>Enables customers to perform long-term historical analysis to scale their automation journeys to the next level</i></p>\n<p><b>NEW YORK, October 13, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/PATH\">UiPath</a> (NYSE: PATH), a leading enterprise automation software company, today announced a partnership with <a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>, the Data Cloud company, that integrates UiPath Insights with Snowflake’s platform. UiPath Insights is a Robotic Process Automation (RPA) analytics solution that measures, reports, and aligns enterprise automation operations with strategic business outcomes. This combined offering of UiPath with Snowflake’s compute, elastic scaling, and enterprise-grade secure data sharing capabilities provides customers with faster data processing, while enabling them to perform long-term historical analysis to scale their automation journeys.</p>\n<p>Along with the spotlight on enterprise automation as a strategic priority comes increased expectations about quantitatively measuring and validating its business impact. UiPath Insights allows business process owners to define, track, measure, and share process key performance indicators (KPIs) that measure the value and impact of a company’s overall automation strategy. Users can easily share dashboards across the company, track the KPIs that matter, and get email push notifications of critical events creating program-wide transparency.</p>\n<p>\"Our partnership with UiPath can help make scalable, secure RPA analytics on Snowflake more accessible to citizen analysts across an organization, to help drive business outcomes,\" said Colleen Kapase, SVP of WorldWide Partnerships at Snowflake. \"As demand for analytics and RPA on Snowflake increases, partnerships with organizations, such as UiPath, help us serve customers globally and support our mission of mobilizing the world’s data.\"</p>\n<p>UiPath and Snowflake can help organizations looking to move to the cloud. Snowflake's comprehensive approach provides customers with the security, since becoming a focal point of today’s data storage conversion and concern. UiPath and Snowflake assure customers in industries such as healthcare, financial services, and insurance that they have what they need to store and analyze their data securely in the cloud.</p>\n<p>\"End-to-end automation can only be fulfilled with a robust analytics platform that can handle today’s explosion of complex data,\" said Dhruv Asher, SVP of Business Development and Product Alliances at UiPath. \"With this new partnership, UiPath and Snowflake will serve the growing market demand to enable our joint customers to accelerate analytics and automation at scale and succeed in their digital transformation initiatives.\"</p>\n<p>As part of today's announcement, UiPath is now recognized as a Powered By Snowflake Partner within the Snowflake Partner Program.</p>\n<p><b>About UiPath</b></p>\n<p>UiPath has a vision to deliver the Fully Automated Enterprise™, <a href=\"https://laohu8.com/S/AONE.U\">one</a> where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UiPath Announces Partnership with Snowflake to Power Robotic Process Automation Analytics in the Cloud</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUiPath Announces Partnership with Snowflake to Power Robotic Process Automation Analytics in the Cloud\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 11:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/uipath-announces-partnership-snowflake-power-120000027.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Enables customers to perform long-term historical analysis to scale their automation journeys to the next level\nNEW YORK, October 13, 2021--(BUSINESS WIRE)--UiPath (NYSE: PATH), a leading enterprise ...</p>\n\n<a href=\"https://finance.yahoo.com/news/uipath-announces-partnership-snowflake-power-120000027.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PATH":"UiPath","SNOW":"Snowflake"},"source_url":"https://finance.yahoo.com/news/uipath-announces-partnership-snowflake-power-120000027.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2175503591","content_text":"Enables customers to perform long-term historical analysis to scale their automation journeys to the next level\nNEW YORK, October 13, 2021--(BUSINESS WIRE)--UiPath (NYSE: PATH), a leading enterprise automation software company, today announced a partnership with Snowflake, the Data Cloud company, that integrates UiPath Insights with Snowflake’s platform. UiPath Insights is a Robotic Process Automation (RPA) analytics solution that measures, reports, and aligns enterprise automation operations with strategic business outcomes. This combined offering of UiPath with Snowflake’s compute, elastic scaling, and enterprise-grade secure data sharing capabilities provides customers with faster data processing, while enabling them to perform long-term historical analysis to scale their automation journeys.\nAlong with the spotlight on enterprise automation as a strategic priority comes increased expectations about quantitatively measuring and validating its business impact. UiPath Insights allows business process owners to define, track, measure, and share process key performance indicators (KPIs) that measure the value and impact of a company’s overall automation strategy. Users can easily share dashboards across the company, track the KPIs that matter, and get email push notifications of critical events creating program-wide transparency.\n\"Our partnership with UiPath can help make scalable, secure RPA analytics on Snowflake more accessible to citizen analysts across an organization, to help drive business outcomes,\" said Colleen Kapase, SVP of WorldWide Partnerships at Snowflake. \"As demand for analytics and RPA on Snowflake increases, partnerships with organizations, such as UiPath, help us serve customers globally and support our mission of mobilizing the world’s data.\"\nUiPath and Snowflake can help organizations looking to move to the cloud. Snowflake's comprehensive approach provides customers with the security, since becoming a focal point of today’s data storage conversion and concern. UiPath and Snowflake assure customers in industries such as healthcare, financial services, and insurance that they have what they need to store and analyze their data securely in the cloud.\n\"End-to-end automation can only be fulfilled with a robust analytics platform that can handle today’s explosion of complex data,\" said Dhruv Asher, SVP of Business Development and Product Alliances at UiPath. \"With this new partnership, UiPath and Snowflake will serve the growing market demand to enable our joint customers to accelerate analytics and automation at scale and succeed in their digital transformation initiatives.\"\nAs part of today's announcement, UiPath is now recognized as a Powered By Snowflake Partner within the Snowflake Partner Program.\nAbout UiPath\nUiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825919513,"gmtCreate":1634188502287,"gmtModify":1634188502361,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Selling mode??","listText":"Selling mode??","text":"Selling mode??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825919513","repostId":"1100517973","repostType":4,"repost":{"id":"1100517973","pubTimestamp":1634183812,"share":"https://www.laohu8.com/m/news/1100517973?lang=&edition=full","pubTime":"2021-10-14 11:56","market":"us","language":"en","title":"FDA Staff Makes No Recommendation on J&J Covid Shot Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=1100517973","media":"Bloomberg","summary":"U.S. regulators didn’t make a recommendation on whether recipients of theJohnson & Johnson Covid-19 ","content":"<p>U.S. regulators didn’t make a recommendation on whether recipients of theJohnson &amp; Johnson&nbsp;Covid-19 vaccine should receive a booster, ahead of a closely watched meeting where scientific experts will weigh whether study data supports giving the additional dose.</p>\n<p>On Friday, the Food and Drug Administration’s advisers will convene to guide the agency on J&amp;J’s request for an emergency-use authorization of a second shot. In a 54-page&nbsp;report&nbsp;released Wednesday in preparation, the agency’s staff didn’t make a formal recommendation for the panel.</p>\n<p>FDA personnel don’t always make a recommendation to the advisory committee. The staff also declined to make a recommendation regarding booster shots from both&nbsp;Moderna Inc.and the&nbsp;Pfizer Inc.-BioNTech SE&nbsp;partnership.</p>\n<p>On Friday, the FDA’s advisers will discuss potential time intervals for the booster to be given. While J&amp;J has recommended a booster at six months or more after the initial shot, it said it may also be administered as early as two months, based on the strength of the immune response.</p>\n<p>J&amp;J’s two-dose results are somewhat complicated because it originally studied the vaccine as a single-dose inoculation. It then conducted a large trial examining the efficacy of two doses given two months apart.</p>\n<p>Separately, the company ran a much smaller trial looking at whether giving a second shot six months after the first raised neutralizing antibodies. Both these trials are part of the company’s booster shot submission.</p>\n<p>Giving two doses of its vaccine two months apart was 94% effective in preventing moderate symptomatic cases of Covid-19 in the U.S., J&amp;J has said. That’s similar to the efficacy rate seen in original final-stage trials of the two-dose messenger RNA vaccines from Moderna and the Pfizer-BioNTech team.</p>\n<p>Booster Interval</p>\n<p>In their report, the FDA staffers said that they had not been able to independently confirm J&amp;J’s findings on the impact of the the two-month interval between the initial shot and the booster. The staff also noted that the margin of error between one- and two-dose efficacy rates overlapped.</p>\n<p>J&amp;J hasn’t reported how a booster delivered six months following the initial dose impacts efficacy against Covid, although it has said a booster at that interval led to a rapid andstrong increase in antibodies.</p>\n<p>U.S. regulators added in their Wednesday report that some data showed that a longer interval between the initial dose and the booster may result in a stronger response in protective neutralizing antibodies.</p>\n<p>In particular, the staff said, there were too few cases of the delta variant in the the two-month interval trial to make any conclusions about efficacy against the strain. However, the two-shot trial results didn’t identify any new safety concerns, the agency said.</p>\n<p>The single-shot vaccine continues to afford protection against severe Covid-19 disease and death in the U.S., the FDA staff report said. And it was still less effective than messenger RNA shots developed from Moderna and the Pfizer-BioNTech team, the staff said.</p>\n<p></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Staff Makes No Recommendation on J&J Covid Shot Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Staff Makes No Recommendation on J&J Covid Shot Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 11:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-13/fda-staff-makes-no-recommendation-on-johnson-johnson-booster><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. regulators didn’t make a recommendation on whether recipients of theJohnson & Johnson Covid-19 vaccine should receive a booster, ahead of a closely watched meeting where scientific experts will ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-13/fda-staff-makes-no-recommendation-on-johnson-johnson-booster\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.bloomberg.com/news/articles/2021-10-13/fda-staff-makes-no-recommendation-on-johnson-johnson-booster","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100517973","content_text":"U.S. regulators didn’t make a recommendation on whether recipients of theJohnson & Johnson Covid-19 vaccine should receive a booster, ahead of a closely watched meeting where scientific experts will weigh whether study data supports giving the additional dose.\nOn Friday, the Food and Drug Administration’s advisers will convene to guide the agency on J&J’s request for an emergency-use authorization of a second shot. In a 54-page report released Wednesday in preparation, the agency’s staff didn’t make a formal recommendation for the panel.\nFDA personnel don’t always make a recommendation to the advisory committee. The staff also declined to make a recommendation regarding booster shots from both Moderna Inc.and the Pfizer Inc.-BioNTech SE partnership.\nOn Friday, the FDA’s advisers will discuss potential time intervals for the booster to be given. While J&J has recommended a booster at six months or more after the initial shot, it said it may also be administered as early as two months, based on the strength of the immune response.\nJ&J’s two-dose results are somewhat complicated because it originally studied the vaccine as a single-dose inoculation. It then conducted a large trial examining the efficacy of two doses given two months apart.\nSeparately, the company ran a much smaller trial looking at whether giving a second shot six months after the first raised neutralizing antibodies. Both these trials are part of the company’s booster shot submission.\nGiving two doses of its vaccine two months apart was 94% effective in preventing moderate symptomatic cases of Covid-19 in the U.S., J&J has said. That’s similar to the efficacy rate seen in original final-stage trials of the two-dose messenger RNA vaccines from Moderna and the Pfizer-BioNTech team.\nBooster Interval\nIn their report, the FDA staffers said that they had not been able to independently confirm J&J’s findings on the impact of the the two-month interval between the initial shot and the booster. The staff also noted that the margin of error between one- and two-dose efficacy rates overlapped.\nJ&J hasn’t reported how a booster delivered six months following the initial dose impacts efficacy against Covid, although it has said a booster at that interval led to a rapid andstrong increase in antibodies.\nU.S. regulators added in their Wednesday report that some data showed that a longer interval between the initial dose and the booster may result in a stronger response in protective neutralizing antibodies.\nIn particular, the staff said, there were too few cases of the delta variant in the the two-month interval trial to make any conclusions about efficacy against the strain. However, the two-shot trial results didn’t identify any new safety concerns, the agency said.\nThe single-shot vaccine continues to afford protection against severe Covid-19 disease and death in the U.S., the FDA staff report said. And it was still less effective than messenger RNA shots developed from Moderna and the Pfizer-BioNTech team, the staff said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":828462928,"gmtCreate":1633937343439,"gmtModify":1633937748581,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hopefully an effective drug for treating Covid.","listText":"Hopefully an effective drug for treating Covid.","text":"Hopefully an effective drug for treating Covid.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/828462928","repostId":"1184886071","repostType":4,"repost":{"id":"1184886071","pubTimestamp":1633937007,"share":"https://www.laohu8.com/m/news/1184886071?lang=&edition=full","pubTime":"2021-10-11 15:23","market":"uk","language":"en","title":"AstraZeneca Antibody Drug Effective at Treating Mild Covid in Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1184886071","media":"Bloomberg","summary":"AstraZeneca Plc’s antibody cocktail was effective at preventing people with mild or moderate Covid-1","content":"<p>AstraZeneca Plc’s&nbsp;antibody cocktail was effective at preventing people with mild or moderate Covid-19 infection from worsening in a study.</p>\n<p>The cocktail halved the risk of developing severe illness or death compared with a placebo in a primary analysis of 822 patients who weren’t hospitalized, Astra said in a statement Monday. The trial took place in countries including the U.K., Brazil, the U.S. and Germany.</p>\n<p>The results are another boon for the product after it was also found to be&nbsp;highly effective&nbsp;at preventing symptomatic Covid in high-risk people. The outcomes are a relief for Astra after an initial trial testing whether the cocktail could prevent symptomatic disease in people explicitly exposed to the virus&nbsp;failed in June. The company said&nbsp;last week it had applied for&nbsp;emergency-use authorization in the U.S.</p>\n<p>Antibody treatments are a key tool in the fight against Covid-19 as they can be used to supplement vaccines for people who haven’t mounted a strong response to the shots or to protect those who couldn’t be immunized. Those who may be eligible for such cocktails include cancer patients or those with weakened immune systems.</p>\n<p>“With continued cases of serious Covid-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations,” said Hugh Montgomery, the principal investigator on the trial and professor of intensive care medicine at University College London.</p>\n<p>In a separate analysis of patients who received treatment within five days of getting symptoms, the cocktail reduced the risk of the disease worsening by 67%. The majority of patients -- 90% -- were from populations at high risk of progression to severe Covid-19, including those with co-morbidities.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Antibody Drug Effective at Treating Mild Covid in Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Antibody Drug Effective at Treating Mild Covid in Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-11 15:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-11/astra-antibody-drug-effective-at-treating-mild-covid-in-trial><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca Plc’s antibody cocktail was effective at preventing people with mild or moderate Covid-19 infection from worsening in a study.\nThe cocktail halved the risk of developing severe illness or ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-11/astra-antibody-drug-effective-at-treating-mild-covid-in-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"source_url":"https://www.bloomberg.com/news/articles/2021-10-11/astra-antibody-drug-effective-at-treating-mild-covid-in-trial","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184886071","content_text":"AstraZeneca Plc’s antibody cocktail was effective at preventing people with mild or moderate Covid-19 infection from worsening in a study.\nThe cocktail halved the risk of developing severe illness or death compared with a placebo in a primary analysis of 822 patients who weren’t hospitalized, Astra said in a statement Monday. The trial took place in countries including the U.K., Brazil, the U.S. and Germany.\nThe results are another boon for the product after it was also found to be highly effective at preventing symptomatic Covid in high-risk people. The outcomes are a relief for Astra after an initial trial testing whether the cocktail could prevent symptomatic disease in people explicitly exposed to the virus failed in June. The company said last week it had applied for emergency-use authorization in the U.S.\nAntibody treatments are a key tool in the fight against Covid-19 as they can be used to supplement vaccines for people who haven’t mounted a strong response to the shots or to protect those who couldn’t be immunized. Those who may be eligible for such cocktails include cancer patients or those with weakened immune systems.\n“With continued cases of serious Covid-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations,” said Hugh Montgomery, the principal investigator on the trial and professor of intensive care medicine at University College London.\nIn a separate analysis of patients who received treatment within five days of getting symptoms, the cocktail reduced the risk of the disease worsening by 67%. The majority of patients -- 90% -- were from populations at high risk of progression to severe Covid-19, including those with co-morbidities.","news_type":1},"isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821308196,"gmtCreate":1633694667882,"gmtModify":1633694668131,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Looks like mostly going up.","listText":"Looks like mostly going up.","text":"Looks like mostly going up.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/821308196","repostId":"1147933296","repostType":4,"repost":{"id":"1147933296","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633693512,"share":"https://www.laohu8.com/m/news/1147933296?lang=&edition=full","pubTime":"2021-10-08 19:45","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1147933296","media":"Tiger Newspress","summary":"(Oct 8) U.S. futures drifted and stocks edged higher as investors awaited a key employment report fo","content":"<p>(Oct&nbsp;8)&nbsp;U.S. futures drifted and stocks edged&nbsp;higher as investors awaited a key employment report for clues on the Federal Reserve’s monetary policy. Treasury yields climbed.</p>\n<p>At 7:47 a.m. ET, Dow E-minis were up 36 points, or 0.10%, S&amp;P 500 E-minis gained&nbsp;5.5 points, or 0.13% and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 E-minis rose 19.5 points, or 0.13%.</p>\n<p><img src=\"https://static.tigerbbs.com/39ee2ce0823e75ecf9646907cb0d8c53\" tg-width=\"1242\" tg-height=\"509\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Here’s what we’re watching ahead of Thursday’s open:</b></p>\n<ul>\n <li>Bitcoin rose 2.4% from its price at 5 p.m. ET on Thursday, and stocks in the crypto world were also gaining. The SEC approved Volt <a href=\"https://laohu8.com/S/EQR\">Equity</a>’s ETF, which aims to track companies that hold a majority of their assets in bitcoin or derive most of their earnings from bitcoin-related activities.Coinbasewas up 1.1% premarket, and bitcoin minerMarathon Digitalgained 2.2%.</li>\n <li><b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a> </b>shares jumped 9.7% premarket after the company said its oral Covid-19 vaccine candidate has shown it could reduce the airborne transmission of the virus in an animal model.</li>\n <li>Fellow vaccine makers&nbsp;Moderna&nbsp;and&nbsp;Novavax,&nbsp;that have suffered price stumbles recently, were also on the rise premarket, up by 0.9% and 1.6% respectively.</li>\n <li>Crude prices are climbing, and shares of energy producers are following them higher.<a href=\"https://laohu8.com/S/OXY\">Occidental</a> Petroleumadded 1.3% premarket,<a href=\"https://laohu8.com/S/DVN\">Devon</a> Energygained 1.8% and oil-services companyHalliburtonrose 1.1%.</li>\n</ul>\n<ul>\n <li><b><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a></b> shares nudged up 0.2% after the electric-car maker said it is&nbsp;moving its headquarters to Austin, Texas, adding to a handful of Silicon Valley companies that have relocated there.</li>\n <li>U.S.-traded shares of&nbsp;Chubb&nbsp;added 0.8% premarket. The Switzerland-based insurer agreed to buy some of&nbsp;Cigna‘s Asia-Pacific operations as part of its strategy to expand in the region.</li>\n <li>Accoladeshares dropped 7.3% premarket after the employee health benefits company reported a loss for the recent quarter.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-08 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct&nbsp;8)&nbsp;U.S. futures drifted and stocks edged&nbsp;higher as investors awaited a key employment report for clues on the Federal Reserve’s monetary policy. Treasury yields climbed.</p>\n<p>At 7:47 a.m. ET, Dow E-minis were up 36 points, or 0.10%, S&amp;P 500 E-minis gained&nbsp;5.5 points, or 0.13% and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 E-minis rose 19.5 points, or 0.13%.</p>\n<p><img src=\"https://static.tigerbbs.com/39ee2ce0823e75ecf9646907cb0d8c53\" tg-width=\"1242\" tg-height=\"509\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Here’s what we’re watching ahead of Thursday’s open:</b></p>\n<ul>\n <li>Bitcoin rose 2.4% from its price at 5 p.m. ET on Thursday, and stocks in the crypto world were also gaining. The SEC approved Volt <a href=\"https://laohu8.com/S/EQR\">Equity</a>’s ETF, which aims to track companies that hold a majority of their assets in bitcoin or derive most of their earnings from bitcoin-related activities.Coinbasewas up 1.1% premarket, and bitcoin minerMarathon Digitalgained 2.2%.</li>\n <li><b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a> </b>shares jumped 9.7% premarket after the company said its oral Covid-19 vaccine candidate has shown it could reduce the airborne transmission of the virus in an animal model.</li>\n <li>Fellow vaccine makers&nbsp;Moderna&nbsp;and&nbsp;Novavax,&nbsp;that have suffered price stumbles recently, were also on the rise premarket, up by 0.9% and 1.6% respectively.</li>\n <li>Crude prices are climbing, and shares of energy producers are following them higher.<a href=\"https://laohu8.com/S/OXY\">Occidental</a> Petroleumadded 1.3% premarket,<a href=\"https://laohu8.com/S/DVN\">Devon</a> Energygained 1.8% and oil-services companyHalliburtonrose 1.1%.</li>\n</ul>\n<ul>\n <li><b><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a></b> shares nudged up 0.2% after the electric-car maker said it is&nbsp;moving its headquarters to Austin, Texas, adding to a handful of Silicon Valley companies that have relocated there.</li>\n <li>U.S.-traded shares of&nbsp;Chubb&nbsp;added 0.8% premarket. The Switzerland-based insurer agreed to buy some of&nbsp;Cigna‘s Asia-Pacific operations as part of its strategy to expand in the region.</li>\n <li>Accoladeshares dropped 7.3% premarket after the employee health benefits company reported a loss for the recent quarter.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147933296","content_text":"(Oct 8) U.S. futures drifted and stocks edged higher as investors awaited a key employment report for clues on the Federal Reserve’s monetary policy. Treasury yields climbed.\nAt 7:47 a.m. ET, Dow E-minis were up 36 points, or 0.10%, S&P 500 E-minis gained 5.5 points, or 0.13% and Nasdaq 100 E-minis rose 19.5 points, or 0.13%.\n\nHere’s what we’re watching ahead of Thursday’s open:\n\nBitcoin rose 2.4% from its price at 5 p.m. ET on Thursday, and stocks in the crypto world were also gaining. The SEC approved Volt Equity’s ETF, which aims to track companies that hold a majority of their assets in bitcoin or derive most of their earnings from bitcoin-related activities.Coinbasewas up 1.1% premarket, and bitcoin minerMarathon Digitalgained 2.2%.\nVaxart, Inc shares jumped 9.7% premarket after the company said its oral Covid-19 vaccine candidate has shown it could reduce the airborne transmission of the virus in an animal model.\nFellow vaccine makers Moderna and Novavax, that have suffered price stumbles recently, were also on the rise premarket, up by 0.9% and 1.6% respectively.\nCrude prices are climbing, and shares of energy producers are following them higher.Occidental Petroleumadded 1.3% premarket,Devon Energygained 1.8% and oil-services companyHalliburtonrose 1.1%.\n\n\nTesla Motors shares nudged up 0.2% after the electric-car maker said it is moving its headquarters to Austin, Texas, adding to a handful of Silicon Valley companies that have relocated there.\nU.S.-traded shares of Chubb added 0.8% premarket. The Switzerland-based insurer agreed to buy some of Cigna‘s Asia-Pacific operations as part of its strategy to expand in the region.\nAccoladeshares dropped 7.3% premarket after the employee health benefits company reported a loss for the recent quarter.","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820061547,"gmtCreate":1633326597666,"gmtModify":1633326752481,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Flying may be open. Unless real urgent and necessary, would be on wait-see mentality as still unsure if any sudden closure or quarantine measure.&nbsp;","listText":"Flying may be open. Unless real urgent and necessary, would be on wait-see mentality as still unsure if any sudden closure or quarantine measure.&nbsp;","text":"Flying may be open. Unless real urgent and necessary, would be on wait-see mentality as still unsure if any sudden closure or quarantine measure.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820061547","repostId":"2172202963","repostType":4,"isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820060428,"gmtCreate":1633326234504,"gmtModify":1633326234700,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"With covid situation,&nbsp; likely to watch programmes at uome. So Netflix should be staying stable","listText":"With covid situation,&nbsp; likely to watch programmes at uome. So Netflix should be staying stable","text":"With covid situation, likely to watch programmes at uome. So Netflix should be staying stable","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/820060428","repostId":"2172964814","repostType":4,"repost":{"id":"2172964814","pubTimestamp":1633319068,"share":"https://www.laohu8.com/m/news/2172964814?lang=&edition=full","pubTime":"2021-10-04 11:44","market":"us","language":"en","title":"Netflix Stock Is Making Record Highs; Could It Keep Going Higher?","url":"https://stock-news.laohu8.com/highlight/detail?id=2172964814","media":"Motley Fool","summary":"The stock benefited from the stay-at-home trend at the pandemic's onset and is maintaining that momentum.","content":"<span> <p><strong>Netflix</strong> <span>(NASDAQ:NFLX)</span> stock made another record high today, closing at $610 on Sept. 30.&nbsp;The company continues to sustain the momentum gained at the pandemic's onset when millions of people turned to Netflix to make the time cooped up at home more enjoyable.&nbsp;</p> <p>Investors were concerned that Netflix could shed some subscribers as economies reopened because people now have more options for spending their time and money on entertainment. That has not been the case thus far. Let's look at some causes for Netflix's stock rise to record highs, and whether it can continue or if it's due for a pullback.&nbsp;</p> \n <div> \n  <img src=\"https://static.tigerbbs.com/c1a5e2d62315ed7229df362a180a2a2e\"> \n  <p>Image source: Getty Images.</p> \n </div> <h2>Netflix is benefiting from the shift to streaming</h2> <p>Interestingly, Netflix is forecasting 3.5 million subscriber additions in its fiscal third quarter. If it hits that target, Netflix will have added a total of 54 million subscribers in the last 24 months. Overall, the company boasts 209 million members that pay to stream movies and shows to their TVs and mobile devices worldwide.</p> <p>The impressive subscriber growth is leading to impressive revenue growth. Indeed, from 2016 to 2020, revenue almost tripled, growing from $8.8 billion to $25 billion. In addition to providing quality service that attracts viewers, Netflix is the beneficiary or arguably the cause of a shift away from linear TV to streaming content. </p> <p>After all, signing up to Netflix is more convenient than a traditional cable subscription. The cable option comes with long-term contracts, a complex installation that requires a professional, and a higher price. In contrast, you can sign up for Netflix and start watching content in minutes, and for less than $1 per day. It's no surprise then that consumers are flocking to the service by the millions.&nbsp;</p> \n <div></div> <p>Still, there is a long runway for this growth to continue as Netflix currently consumes less overall attention from viewers than linear TV. </p> <h2>Netflix is growing efficiently&nbsp;</h2> <p>Moreover, Netflix is managing its growth efficiently. The company is not spending on content with reckless abandon. Management looks at how much revenue will come in for a given quarter or year and plans content spending based on that revenue total, making sure to leave room for steady operating profit expansion. Since January 2016, management has committed to a goal of increasing operating profit margin by 300 basis points per year, and so far, it is hitting the target (see chart).&nbsp;</p> \n <div> \n  <img src=\"https://static.tigerbbs.com/235bd6191e48fb938ef3f3835309e52b\"> \n  <p>Data by YCharts.</p> \n </div> <h2>Is Netflix stock expensive?&nbsp;</h2> <p>A common question arises whenever a stock rises to record highs: Is the stock too expensive to buy? The critical thing to note with Netflix is that its profits are rising along with its stock price. Over the last five years, earnings per share have increased substantially: starting with $0.43 in 2016, $1.25 in 2017, $2.68 in 2018, $4.13 in 2019, and $6.08 in 2020. </p> <p>That means even though Netflix stock is at record highs, it's trading for a price-to-earnings ratio (63) near the cheapest level in the last decade. To answer my question, Netflix is not expensive, and given its solid prospects, it can continue going even higher. </p> \n <div></div> \n <div></div> </span>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix Stock Is Making Record Highs; Could It Keep Going Higher?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix Stock Is Making Record Highs; Could It Keep Going Higher?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 11:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/02/netflix-stock-makes-record-is-it-too-late-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Netflix (NASDAQ:NFLX) stock made another record high today, closing at $610 on Sept. 30. The company continues to sustain the momentum gained at the pandemic's onset when millions of people turned to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/02/netflix-stock-makes-record-is-it-too-late-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞"},"source_url":"https://www.fool.com/investing/2021/10/02/netflix-stock-makes-record-is-it-too-late-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172964814","content_text":"Netflix (NASDAQ:NFLX) stock made another record high today, closing at $610 on Sept. 30. The company continues to sustain the momentum gained at the pandemic's onset when millions of people turned to Netflix to make the time cooped up at home more enjoyable.  Investors were concerned that Netflix could shed some subscribers as economies reopened because people now have more options for spending their time and money on entertainment. That has not been the case thus far. Let's look at some causes for Netflix's stock rise to record highs, and whether it can continue or if it's due for a pullback. \n\n\nImage source: Getty Images.\n Netflix is benefiting from the shift to streaming Interestingly, Netflix is forecasting 3.5 million subscriber additions in its fiscal third quarter. If it hits that target, Netflix will have added a total of 54 million subscribers in the last 24 months. Overall, the company boasts 209 million members that pay to stream movies and shows to their TVs and mobile devices worldwide. The impressive subscriber growth is leading to impressive revenue growth. Indeed, from 2016 to 2020, revenue almost tripled, growing from $8.8 billion to $25 billion. In addition to providing quality service that attracts viewers, Netflix is the beneficiary or arguably the cause of a shift away from linear TV to streaming content.  After all, signing up to Netflix is more convenient than a traditional cable subscription. The cable option comes with long-term contracts, a complex installation that requires a professional, and a higher price. In contrast, you can sign up for Netflix and start watching content in minutes, and for less than $1 per day. It's no surprise then that consumers are flocking to the service by the millions. \n Still, there is a long runway for this growth to continue as Netflix currently consumes less overall attention from viewers than linear TV.  Netflix is growing efficiently  Moreover, Netflix is managing its growth efficiently. The company is not spending on content with reckless abandon. Management looks at how much revenue will come in for a given quarter or year and plans content spending based on that revenue total, making sure to leave room for steady operating profit expansion. Since January 2016, management has committed to a goal of increasing operating profit margin by 300 basis points per year, and so far, it is hitting the target (see chart). \n\n\nData by YCharts.\n Is Netflix stock expensive?  A common question arises whenever a stock rises to record highs: Is the stock too expensive to buy? The critical thing to note with Netflix is that its profits are rising along with its stock price. Over the last five years, earnings per share have increased substantially: starting with $0.43 in 2016, $1.25 in 2017, $2.68 in 2018, $4.13 in 2019, and $6.08 in 2020.  That means even though Netflix stock is at record highs, it's trading for a price-to-earnings ratio (63) near the cheapest level in the last decade. To answer my question, Netflix is not expensive, and given its solid prospects, it can continue going even higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865386635,"gmtCreate":1632954198567,"gmtModify":1632954198777,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Positive or negative? Hopeful","listText":"Positive or negative? Hopeful","text":"Positive or negative? Hopeful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865386635","repostId":"2171980870","repostType":4,"isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":879203385,"gmtCreate":1636725208738,"gmtModify":1636725274754,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hmmm looks like can consider Exelixis&nbsp;","listText":"Hmmm looks like can consider Exelixis&nbsp;","text":"Hmmm looks like can consider Exelixis","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879203385","repostId":"2182094779","repostType":4,"repost":{"id":"2182094779","pubTimestamp":1636723680,"share":"https://www.laohu8.com/m/news/2182094779?lang=&edition=full","pubTime":"2021-11-12 21:28","market":"us","language":"en","title":"The Smartest Stocks to Buy With $20 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2182094779","media":"Motley Fool","summary":"A small amount of money can go a long way when invested in these top-notch stocks.","content":"<p>Time and again, Wall Street has shown investors the power of patience.</p>\n<p>Over the past 71 years, the broad-based <b>S&amp;P 500</b> has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.</p>\n<p>Best of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.</p>\n<h2>Exelixis</h2>\n<p>One of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer <b>Exelixis</b> (NASDAQ:EXEL).</p>\n<p>Last week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.</p>\n<p>However, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"</p>\n<p>Although the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.</p>\n<p>More importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.</p>\n<p>Additionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.</p>\n<p>It's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.</p>\n<h2>Jushi Holdings</h2>\n<p>Some of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) <b>Jushi Holdings</b> (OTC:JUSHF) makes for a smart buy with $20.</p>\n<p>To start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.</p>\n<p>In relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.</p>\n<p>The reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.</p>\n<p>Something else impressive about Jushi, and <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.</p>\n<p>Jushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.</p>\n<h2>Viatris</h2>\n<p>On the other hand, if value runs through your blood, generic-drug giant <b>Viatris</b> (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.</p>\n<p>Roughly a year ago, Viatris was born from the combination of <b>Pfizer</b>'s established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.</p>\n<p>There were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.</p>\n<p>As a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.</p>\n<p>Beyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.</p>\n<p>Viatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $20 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $20 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯","JUSHF":"Jushi Holdings Inc.","VTRS":"Viatris Inc."},"source_url":"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2182094779","content_text":"Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.\nBest of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.\nExelixis\nOne of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer Exelixis (NASDAQ:EXEL).\nLast week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.\nHowever, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"\nAlthough the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.\nMore importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.\nAdditionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.\nIt's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.\nJushi Holdings\nSome of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) Jushi Holdings (OTC:JUSHF) makes for a smart buy with $20.\nTo start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.\nIn relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.\nThe reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.\nSomething else impressive about Jushi, and one of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.\nJushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.\nViatris\nOn the other hand, if value runs through your blood, generic-drug giant Viatris (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.\nRoughly a year ago, Viatris was born from the combination of Pfizer's established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.\nThere were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.\nAs a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.\nBeyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.\nViatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.","news_type":1},"isVote":1,"tweetType":1,"viewCount":942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825911544,"gmtCreate":1634188667408,"gmtModify":1634188667522,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Not many have courage to buy at dying moments","listText":"Not many have courage to buy at dying moments","text":"Not many have courage to buy at dying moments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/825911544","repostId":"1111412750","repostType":4,"repost":{"id":"1111412750","pubTimestamp":1634182832,"share":"https://www.laohu8.com/m/news/1111412750?lang=&edition=full","pubTime":"2021-10-14 11:40","market":"us","language":"en","title":"Buying The Dip Is Dead","url":"https://stock-news.laohu8.com/highlight/detail?id=1111412750","media":"seekingalpha","summary":"Summary\n\nBuying the dip died when the volatility sellers failed to show up.\nThere's a mechanical rea","content":"<p>Summary</p>\n<ul>\n <li>Buying the dip died when the volatility sellers failed to show up.</li>\n <li>There's a mechanical reason why the market has not \"bounced back.\"</li>\n <li>That mechanical reason has broken down due to fundamental shifts.</li>\n</ul>\n<p>The market has been melting, and that \"buy the dip\" mentality seems to be in trouble. There's an excellent reason for why buying the dip hasn't worked, and probably why it won't work this time around either. All you have to do is look at the VIX and the SKEW indexes to understand why.</p>\n<p>Falling volatility has been a lynchpin of propping up the market every time it falters since the COVID low. Every time the market sank, the VIX would spike higher. Then, a swarm of traders would come in looking to short volatility, which would send the VIX lower, pushing the S&amp;P 500 higher. However, that component of the market appears to be gone. The VIX has been steadily rising since June, with higher lows. More recently, the VIX hasn't been able to get below 18, and each drop in the S&amp;P 500 has seen lower highs.</p>\n<p><img src=\"https://static.tigerbbs.com/7d40186560f397cc6ebdc4e85ba18725\" tg-width=\"640\" tg-height=\"397\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Additionally, the SKEW index has cratered in recent weeks. It's because traders that have been betting on volatility falling have likely been shorting at-the-money forms of it, and to hedge those positions, they have been buying out-of-money forms. It's why the SKEW index reached record highs in June as the VIX hit its lows.</p>\n<p>The SKEW index wasn't rising into June 2021 because traders were trying to hedge against tail risk or an unforeseen event. The SKEW index was rising as a hedge against short volatility positions.</p>\n<p>If volatility sellers do not return to this market, then a big piece of why the market always has been able to bounce back so quickly on every dip will be gone. Buying the dip will simply not work.</p>\n<p><img src=\"https://static.tigerbbs.com/d92c33e67c289d5c9d1e8d0d6ec74b5d\" tg-width=\"640\" tg-height=\"397\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>But with QE likely on its way out, financial conditions are likely to tighten as a result. It seems that volatility sellers have gone missing for a good reason. If that's the case, the considerable risk in the market isn't going to be the fear of missing out. The substantial risk is a meltdown, not all that&nbsp;dissimilar to that of 2018, which I have noted on several occasions many of the same similarities of today to back then.</p>\n<p>The dollar index may be a big piece of that. It has been surging higher, and that the S&amp;P 500 has been trading precisely the opposite to the dollar's move. When the dollar has been strengthening, the S&amp;P 500 has been falling and vice versa. The&nbsp;dollar is telling us that tapering&nbsp;is coming and very soon. The stock market knows what this means too, and it isn't good for stocks.</p>\n<p>The two-year Treasury rate has also been creeping higher and now stands at more than 35 bps. The two-year most likely needs to rise much more if the Fed is tapering. By the time the QE taper ended in October 2014, the two-year was around 50 to 60 bps. That means the&nbsp;two-year&nbsp;now has further to climb as this process commences potentially as soon as the November FOMC meeting.</p>\n<p>Despite the stronger dollar, the 10-year has been falling, and that's because the market is picking up on what I have been telling you for months. Growth rates here in the US and around the globe have been slowing and are now near stall speed. They have gotten so slow here in the US that the Atlanta Fed GDPNow is now projecting just a 1.3% third quarter growth rate, an enormous drop from the second-quarter reading of 6.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/ce210603773584da38e4fbf054f31ba9\" tg-width=\"640\" tg-height=\"480\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The market knows that a strong dollar in regular times exports inflationary forces aboard in countries that buy commodities, finances debt, or conduct business in dollars. It's a global growth killer. On top of that, rising prices for things like energy are already likely to slow growth, and now with the dollar rising, it makes the problem even more prominent. It is driving the rates on the long-end of the curve lower and flattening the yield curve.</p>\n<p>This time is different from previous pullbacks. This is why this time the pullback is only in its early phases. Earnings estimates have started to come down, and they are likely to come down further because if one thing is crystal clear, GDP growth expectations were way off base, and means that it is highly likely that&nbsp;earnings estimates&nbsp;are way off base, which means earnings growth rates will be heading lower or top of what they have declined.</p>\n<p><img src=\"https://static.tigerbbs.com/b784f4142c7b91a6c36b4c8d263db047\" tg-width=\"640\" tg-height=\"480\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>It's just a matter of when the stock market realizes that a Fed tapering event will push the dollar index even higher at the worst possible time resulting in a massive global growth scare. Perhaps the biggest reason why the volatility sellers have left the building.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buying The Dip Is Dead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuying The Dip Is Dead\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4459696-buying-the-dip-is-dead><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nBuying the dip died when the volatility sellers failed to show up.\nThere's a mechanical reason why the market has not \"bounced back.\"\nThat mechanical reason has broken down due to fundamental...</p>\n\n<a href=\"https://seekingalpha.com/article/4459696-buying-the-dip-is-dead\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://seekingalpha.com/article/4459696-buying-the-dip-is-dead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111412750","content_text":"Summary\n\nBuying the dip died when the volatility sellers failed to show up.\nThere's a mechanical reason why the market has not \"bounced back.\"\nThat mechanical reason has broken down due to fundamental shifts.\n\nThe market has been melting, and that \"buy the dip\" mentality seems to be in trouble. There's an excellent reason for why buying the dip hasn't worked, and probably why it won't work this time around either. All you have to do is look at the VIX and the SKEW indexes to understand why.\nFalling volatility has been a lynchpin of propping up the market every time it falters since the COVID low. Every time the market sank, the VIX would spike higher. Then, a swarm of traders would come in looking to short volatility, which would send the VIX lower, pushing the S&P 500 higher. However, that component of the market appears to be gone. The VIX has been steadily rising since June, with higher lows. More recently, the VIX hasn't been able to get below 18, and each drop in the S&P 500 has seen lower highs.\n\nAdditionally, the SKEW index has cratered in recent weeks. It's because traders that have been betting on volatility falling have likely been shorting at-the-money forms of it, and to hedge those positions, they have been buying out-of-money forms. It's why the SKEW index reached record highs in June as the VIX hit its lows.\nThe SKEW index wasn't rising into June 2021 because traders were trying to hedge against tail risk or an unforeseen event. The SKEW index was rising as a hedge against short volatility positions.\nIf volatility sellers do not return to this market, then a big piece of why the market always has been able to bounce back so quickly on every dip will be gone. Buying the dip will simply not work.\n\nBut with QE likely on its way out, financial conditions are likely to tighten as a result. It seems that volatility sellers have gone missing for a good reason. If that's the case, the considerable risk in the market isn't going to be the fear of missing out. The substantial risk is a meltdown, not all that dissimilar to that of 2018, which I have noted on several occasions many of the same similarities of today to back then.\nThe dollar index may be a big piece of that. It has been surging higher, and that the S&P 500 has been trading precisely the opposite to the dollar's move. When the dollar has been strengthening, the S&P 500 has been falling and vice versa. The dollar is telling us that tapering is coming and very soon. The stock market knows what this means too, and it isn't good for stocks.\nThe two-year Treasury rate has also been creeping higher and now stands at more than 35 bps. The two-year most likely needs to rise much more if the Fed is tapering. By the time the QE taper ended in October 2014, the two-year was around 50 to 60 bps. That means the two-year now has further to climb as this process commences potentially as soon as the November FOMC meeting.\nDespite the stronger dollar, the 10-year has been falling, and that's because the market is picking up on what I have been telling you for months. Growth rates here in the US and around the globe have been slowing and are now near stall speed. They have gotten so slow here in the US that the Atlanta Fed GDPNow is now projecting just a 1.3% third quarter growth rate, an enormous drop from the second-quarter reading of 6.7%.\n\nThe market knows that a strong dollar in regular times exports inflationary forces aboard in countries that buy commodities, finances debt, or conduct business in dollars. It's a global growth killer. On top of that, rising prices for things like energy are already likely to slow growth, and now with the dollar rising, it makes the problem even more prominent. It is driving the rates on the long-end of the curve lower and flattening the yield curve.\nThis time is different from previous pullbacks. This is why this time the pullback is only in its early phases. Earnings estimates have started to come down, and they are likely to come down further because if one thing is crystal clear, GDP growth expectations were way off base, and means that it is highly likely that earnings estimates are way off base, which means earnings growth rates will be heading lower or top of what they have declined.\n\nIt's just a matter of when the stock market realizes that a Fed tapering event will push the dollar index even higher at the worst possible time resulting in a massive global growth scare. Perhaps the biggest reason why the volatility sellers have left the building.","news_type":1},"isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820060428,"gmtCreate":1633326234504,"gmtModify":1633326234700,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"With covid situation,&nbsp; likely to watch programmes at uome. So Netflix should be staying stable","listText":"With covid situation,&nbsp; likely to watch programmes at uome. So Netflix should be staying stable","text":"With covid situation, likely to watch programmes at uome. So Netflix should be staying stable","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/820060428","repostId":"2172964814","repostType":4,"repost":{"id":"2172964814","pubTimestamp":1633319068,"share":"https://www.laohu8.com/m/news/2172964814?lang=&edition=full","pubTime":"2021-10-04 11:44","market":"us","language":"en","title":"Netflix Stock Is Making Record Highs; Could It Keep Going Higher?","url":"https://stock-news.laohu8.com/highlight/detail?id=2172964814","media":"Motley Fool","summary":"The stock benefited from the stay-at-home trend at the pandemic's onset and is maintaining that momentum.","content":"<span> <p><strong>Netflix</strong> <span>(NASDAQ:NFLX)</span> stock made another record high today, closing at $610 on Sept. 30.&nbsp;The company continues to sustain the momentum gained at the pandemic's onset when millions of people turned to Netflix to make the time cooped up at home more enjoyable.&nbsp;</p> <p>Investors were concerned that Netflix could shed some subscribers as economies reopened because people now have more options for spending their time and money on entertainment. That has not been the case thus far. Let's look at some causes for Netflix's stock rise to record highs, and whether it can continue or if it's due for a pullback.&nbsp;</p> \n <div> \n  <img src=\"https://static.tigerbbs.com/c1a5e2d62315ed7229df362a180a2a2e\"> \n  <p>Image source: Getty Images.</p> \n </div> <h2>Netflix is benefiting from the shift to streaming</h2> <p>Interestingly, Netflix is forecasting 3.5 million subscriber additions in its fiscal third quarter. If it hits that target, Netflix will have added a total of 54 million subscribers in the last 24 months. Overall, the company boasts 209 million members that pay to stream movies and shows to their TVs and mobile devices worldwide.</p> <p>The impressive subscriber growth is leading to impressive revenue growth. Indeed, from 2016 to 2020, revenue almost tripled, growing from $8.8 billion to $25 billion. In addition to providing quality service that attracts viewers, Netflix is the beneficiary or arguably the cause of a shift away from linear TV to streaming content. </p> <p>After all, signing up to Netflix is more convenient than a traditional cable subscription. The cable option comes with long-term contracts, a complex installation that requires a professional, and a higher price. In contrast, you can sign up for Netflix and start watching content in minutes, and for less than $1 per day. It's no surprise then that consumers are flocking to the service by the millions.&nbsp;</p> \n <div></div> <p>Still, there is a long runway for this growth to continue as Netflix currently consumes less overall attention from viewers than linear TV. </p> <h2>Netflix is growing efficiently&nbsp;</h2> <p>Moreover, Netflix is managing its growth efficiently. The company is not spending on content with reckless abandon. Management looks at how much revenue will come in for a given quarter or year and plans content spending based on that revenue total, making sure to leave room for steady operating profit expansion. Since January 2016, management has committed to a goal of increasing operating profit margin by 300 basis points per year, and so far, it is hitting the target (see chart).&nbsp;</p> \n <div> \n  <img src=\"https://static.tigerbbs.com/235bd6191e48fb938ef3f3835309e52b\"> \n  <p>Data by YCharts.</p> \n </div> <h2>Is Netflix stock expensive?&nbsp;</h2> <p>A common question arises whenever a stock rises to record highs: Is the stock too expensive to buy? The critical thing to note with Netflix is that its profits are rising along with its stock price. Over the last five years, earnings per share have increased substantially: starting with $0.43 in 2016, $1.25 in 2017, $2.68 in 2018, $4.13 in 2019, and $6.08 in 2020. </p> <p>That means even though Netflix stock is at record highs, it's trading for a price-to-earnings ratio (63) near the cheapest level in the last decade. To answer my question, Netflix is not expensive, and given its solid prospects, it can continue going even higher. </p> \n <div></div> \n <div></div> </span>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix Stock Is Making Record Highs; Could It Keep Going Higher?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix Stock Is Making Record Highs; Could It Keep Going Higher?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 11:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/02/netflix-stock-makes-record-is-it-too-late-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Netflix (NASDAQ:NFLX) stock made another record high today, closing at $610 on Sept. 30. The company continues to sustain the momentum gained at the pandemic's onset when millions of people turned to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/02/netflix-stock-makes-record-is-it-too-late-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞"},"source_url":"https://www.fool.com/investing/2021/10/02/netflix-stock-makes-record-is-it-too-late-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172964814","content_text":"Netflix (NASDAQ:NFLX) stock made another record high today, closing at $610 on Sept. 30. The company continues to sustain the momentum gained at the pandemic's onset when millions of people turned to Netflix to make the time cooped up at home more enjoyable.  Investors were concerned that Netflix could shed some subscribers as economies reopened because people now have more options for spending their time and money on entertainment. That has not been the case thus far. Let's look at some causes for Netflix's stock rise to record highs, and whether it can continue or if it's due for a pullback. \n\n\nImage source: Getty Images.\n Netflix is benefiting from the shift to streaming Interestingly, Netflix is forecasting 3.5 million subscriber additions in its fiscal third quarter. If it hits that target, Netflix will have added a total of 54 million subscribers in the last 24 months. Overall, the company boasts 209 million members that pay to stream movies and shows to their TVs and mobile devices worldwide. The impressive subscriber growth is leading to impressive revenue growth. Indeed, from 2016 to 2020, revenue almost tripled, growing from $8.8 billion to $25 billion. In addition to providing quality service that attracts viewers, Netflix is the beneficiary or arguably the cause of a shift away from linear TV to streaming content.  After all, signing up to Netflix is more convenient than a traditional cable subscription. The cable option comes with long-term contracts, a complex installation that requires a professional, and a higher price. In contrast, you can sign up for Netflix and start watching content in minutes, and for less than $1 per day. It's no surprise then that consumers are flocking to the service by the millions. \n Still, there is a long runway for this growth to continue as Netflix currently consumes less overall attention from viewers than linear TV.  Netflix is growing efficiently  Moreover, Netflix is managing its growth efficiently. The company is not spending on content with reckless abandon. Management looks at how much revenue will come in for a given quarter or year and plans content spending based on that revenue total, making sure to leave room for steady operating profit expansion. Since January 2016, management has committed to a goal of increasing operating profit margin by 300 basis points per year, and so far, it is hitting the target (see chart). \n\n\nData by YCharts.\n Is Netflix stock expensive?  A common question arises whenever a stock rises to record highs: Is the stock too expensive to buy? The critical thing to note with Netflix is that its profits are rising along with its stock price. Over the last five years, earnings per share have increased substantially: starting with $0.43 in 2016, $1.25 in 2017, $2.68 in 2018, $4.13 in 2019, and $6.08 in 2020.  That means even though Netflix stock is at record highs, it's trading for a price-to-earnings ratio (63) near the cheapest level in the last decade. To answer my question, Netflix is not expensive, and given its solid prospects, it can continue going even higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606007577,"gmtCreate":1638798648742,"gmtModify":1638799923736,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"It's December vacation drop time","listText":"It's December vacation drop time","text":"It's December vacation drop time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606007577","repostId":"1191091006","repostType":4,"repost":{"id":"1191091006","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638796414,"share":"https://www.laohu8.com/m/news/1191091006?lang=&edition=full","pubTime":"2021-12-06 21:13","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1191091006","media":"Tiger Newspress","summary":"The Nasdaq index was set for a lower open on Monday as mega-cap technology firms slipped and shares ","content":"<p>The Nasdaq index was set for a lower open on Monday as mega-cap technology firms slipped and shares of Nvidia led declines among major chipmakers, while Dow futures were supported by a rise in economy-sensitive stocks.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 198 points, or 0.57%, S&amp;P 500 e-minis were up 10.25 points, or 0.23%, and Nasdaq 100 e-minis were down 55.75 points, or 0.35%.</p>\n<p><img src=\"https://static.tigerbbs.com/1463820447570ba6f65ee49e1b05c085\" tg-width=\"1080\" tg-height=\"384\" referrerpolicy=\"no-referrer\"></p>\n<p>Stocks exposed to cryptocurrencies plunged in premarket trading on Monday as Bitcoin’s retreat from the record high it reached last month ballooned to nearly 30%.Marathon Digital,Riot Blockchain,Ebang international,Coinbase,BIT Mining,Canaan and SoS Ltd fell between 4% and 10%.</p>\n<p>After a mixed jobs report last week, focus will now be on the release of consumer price index and core inflation readings on Friday for clues on the trajectory of the Fed's policy decision at its December meeting.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b>Nvidia(NVDA) </b>– The graphics chip maker’s stock slid 4.3% in the premarket, as it deals with continuing obstacles to its planned takeover of British chipmaker ARM. EU antitrust regulators have halted their investigation of the deal as they await more information, and last week the U.S. FTC sued to block the transaction.</p>\n<p><b>Lucid Group(LCID)</b> – The electric vehicle maker’s stock slumped 14.7% in premarket trading after it received a subpoena from the Securities and Exchange Commission. Lucid said the subpoena requested documents related to its SPAC merger deal with Churchill Capital Corp.</p>\n<p><b>Tesla(</b><b>TSLA</b><b>)</b><b>&nbsp;</b>–&nbsp;Tesla stock dropped nearly 3% in premarket trading&nbsp;after&nbsp;the SEC launched an investigation into the informant's claim that Tesla solar panels were defective.In addition,Tesla&nbsp;recalled 21,599 Model Ys made in China, citing steering knuckle issues.</p>\n<p><b>Alibaba(BABA) </b>– The China-based e-commerce giant saw its shares add 1% in premarket action after it announced a reorganization of its e-commerce teams and named a new chief financial officer.</p>\n<p><b>CF Acquisition Corp VI(CFVI)</b>&nbsp;–&nbsp;YouTube competitor Rumble&nbsp;would&nbsp;go public via SPAC CF Acquisition VI.CF Acquisition Corp VI stock jumped 23% in premarket trading.</p>\n<p><b>Digital World Acquisition(DWAC)</b>&nbsp;–&nbsp;Digital World Acquisition stock surged 10% in premarket trading.Trump's social media venture says it has raised $1 bln.</p>\n<p><b>Kohl’s(KSS)</b> – The retailer’s stock rallied 4.2% in the premarket following news that activist investor Engine Capital is urging Kohl’s to consider either a sale of the company or a separation of its e-commerce business. Engine Capital has a Kohl’s stake of approximately 1%.</p>\n<p><b>Electronic Arts(EA)</b> – The video game maker gained 1.9% in premarket trading after Citi upgraded the stock to “buy” from “neutral.” Citi said the recent slide presents a buying opportunity despite concerns over factors like the weakness in EA’s “Battlefield 2042” title.</p>\n<p><b>GCP Applied Technologies(GCP)</b> – The maker of specialty construction chemicals agreed to be acquired by French construction company Saint-Gobain for $32 per share in cash, or about $32 billion. GCP surged 14.4% in premarket trading.</p>\n<p><b>FactSet Research(FDS) </b>– The provider of financial information will join the S&amp;P 500 prior to the market opening on December 20, along with&nbsp;Signature Bank(SBNY) and&nbsp;SolarEdge Technologies(SEDG). They’ll replaceLeggett &amp; Platt(LEG),Hanesbrands(HBI), and&nbsp;Western Union(WU), which will all move to the S&amp;P MidCap 400.</p>\n<p><b>MicroStrategy(MSTR) </b>– MicroStrategy tumbled 7.6% in the premarket following the weekend slide in the price of bitcoin. The business analytics software company has billions of dollars in bitcoin holdings on its balance sheet.</p>\n<p><b>Spirit Airlines(SAVE) </b>– Spirit rose 1.4% in the premarket after Evercore upgraded the airline’s stock to “outperform” from “in-line,” saying the company winds up in a better place each time it goes through a recovery cycle.</p>\n<p><b>Wells Fargo(WFC) </b>– The bank was named a “top pick” at Morgan Stanley, which notes that faster interest rate hikes will benefit the banking sector and that the omicron Covid-19 variant will only push recovery out by a quarter or so. Wells Fargo shares added 1.4% in the premarket.</p>\n<p><b>Boston Beer(SAM) </b>– The brewer’s stock added 1.2% in premarket action, following a Cowen upgrade to “market perform” from “underperform”. Cowen notes the slump in the stock price since August, but said it sees signs of stabilization and negative revisions to earnings are now priced into the stock.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-06 21:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The Nasdaq index was set for a lower open on Monday as mega-cap technology firms slipped and shares of Nvidia led declines among major chipmakers, while Dow futures were supported by a rise in economy-sensitive stocks.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 198 points, or 0.57%, S&amp;P 500 e-minis were up 10.25 points, or 0.23%, and Nasdaq 100 e-minis were down 55.75 points, or 0.35%.</p>\n<p><img src=\"https://static.tigerbbs.com/1463820447570ba6f65ee49e1b05c085\" tg-width=\"1080\" tg-height=\"384\" referrerpolicy=\"no-referrer\"></p>\n<p>Stocks exposed to cryptocurrencies plunged in premarket trading on Monday as Bitcoin’s retreat from the record high it reached last month ballooned to nearly 30%.Marathon Digital,Riot Blockchain,Ebang international,Coinbase,BIT Mining,Canaan and SoS Ltd fell between 4% and 10%.</p>\n<p>After a mixed jobs report last week, focus will now be on the release of consumer price index and core inflation readings on Friday for clues on the trajectory of the Fed's policy decision at its December meeting.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b>Nvidia(NVDA) </b>– The graphics chip maker’s stock slid 4.3% in the premarket, as it deals with continuing obstacles to its planned takeover of British chipmaker ARM. EU antitrust regulators have halted their investigation of the deal as they await more information, and last week the U.S. FTC sued to block the transaction.</p>\n<p><b>Lucid Group(LCID)</b> – The electric vehicle maker’s stock slumped 14.7% in premarket trading after it received a subpoena from the Securities and Exchange Commission. Lucid said the subpoena requested documents related to its SPAC merger deal with Churchill Capital Corp.</p>\n<p><b>Tesla(</b><b>TSLA</b><b>)</b><b>&nbsp;</b>–&nbsp;Tesla stock dropped nearly 3% in premarket trading&nbsp;after&nbsp;the SEC launched an investigation into the informant's claim that Tesla solar panels were defective.In addition,Tesla&nbsp;recalled 21,599 Model Ys made in China, citing steering knuckle issues.</p>\n<p><b>Alibaba(BABA) </b>– The China-based e-commerce giant saw its shares add 1% in premarket action after it announced a reorganization of its e-commerce teams and named a new chief financial officer.</p>\n<p><b>CF Acquisition Corp VI(CFVI)</b>&nbsp;–&nbsp;YouTube competitor Rumble&nbsp;would&nbsp;go public via SPAC CF Acquisition VI.CF Acquisition Corp VI stock jumped 23% in premarket trading.</p>\n<p><b>Digital World Acquisition(DWAC)</b>&nbsp;–&nbsp;Digital World Acquisition stock surged 10% in premarket trading.Trump's social media venture says it has raised $1 bln.</p>\n<p><b>Kohl’s(KSS)</b> – The retailer’s stock rallied 4.2% in the premarket following news that activist investor Engine Capital is urging Kohl’s to consider either a sale of the company or a separation of its e-commerce business. Engine Capital has a Kohl’s stake of approximately 1%.</p>\n<p><b>Electronic Arts(EA)</b> – The video game maker gained 1.9% in premarket trading after Citi upgraded the stock to “buy” from “neutral.” Citi said the recent slide presents a buying opportunity despite concerns over factors like the weakness in EA’s “Battlefield 2042” title.</p>\n<p><b>GCP Applied Technologies(GCP)</b> – The maker of specialty construction chemicals agreed to be acquired by French construction company Saint-Gobain for $32 per share in cash, or about $32 billion. GCP surged 14.4% in premarket trading.</p>\n<p><b>FactSet Research(FDS) </b>– The provider of financial information will join the S&amp;P 500 prior to the market opening on December 20, along with&nbsp;Signature Bank(SBNY) and&nbsp;SolarEdge Technologies(SEDG). They’ll replaceLeggett &amp; Platt(LEG),Hanesbrands(HBI), and&nbsp;Western Union(WU), which will all move to the S&amp;P MidCap 400.</p>\n<p><b>MicroStrategy(MSTR) </b>– MicroStrategy tumbled 7.6% in the premarket following the weekend slide in the price of bitcoin. The business analytics software company has billions of dollars in bitcoin holdings on its balance sheet.</p>\n<p><b>Spirit Airlines(SAVE) </b>– Spirit rose 1.4% in the premarket after Evercore upgraded the airline’s stock to “outperform” from “in-line,” saying the company winds up in a better place each time it goes through a recovery cycle.</p>\n<p><b>Wells Fargo(WFC) </b>– The bank was named a “top pick” at Morgan Stanley, which notes that faster interest rate hikes will benefit the banking sector and that the omicron Covid-19 variant will only push recovery out by a quarter or so. Wells Fargo shares added 1.4% in the premarket.</p>\n<p><b>Boston Beer(SAM) </b>– The brewer’s stock added 1.2% in premarket action, following a Cowen upgrade to “market perform” from “underperform”. Cowen notes the slump in the stock price since August, but said it sees signs of stabilization and negative revisions to earnings are now priced into the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","BABA":"阿里巴巴","WFC":"富国银行","SAVE":"Spirit Airlines","SAM":"波斯顿啤酒","EA":"艺电","LCID":"Lucid Group Inc",".DJI":"道琼斯","FDS":"辉盛研究系统","MSTR":"MicroStrategy Incorporated","TSLA":"特斯拉","KSS":"柯尔百货",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191091006","content_text":"The Nasdaq index was set for a lower open on Monday as mega-cap technology firms slipped and shares of Nvidia led declines among major chipmakers, while Dow futures were supported by a rise in economy-sensitive stocks.\nAt 8:00 a.m. ET, Dow e-minis were up 198 points, or 0.57%, S&P 500 e-minis were up 10.25 points, or 0.23%, and Nasdaq 100 e-minis were down 55.75 points, or 0.35%.\n\nStocks exposed to cryptocurrencies plunged in premarket trading on Monday as Bitcoin’s retreat from the record high it reached last month ballooned to nearly 30%.Marathon Digital,Riot Blockchain,Ebang international,Coinbase,BIT Mining,Canaan and SoS Ltd fell between 4% and 10%.\nAfter a mixed jobs report last week, focus will now be on the release of consumer price index and core inflation readings on Friday for clues on the trajectory of the Fed's policy decision at its December meeting.\nStocks making the biggest moves premarket: \nNvidia(NVDA) – The graphics chip maker’s stock slid 4.3% in the premarket, as it deals with continuing obstacles to its planned takeover of British chipmaker ARM. EU antitrust regulators have halted their investigation of the deal as they await more information, and last week the U.S. FTC sued to block the transaction.\nLucid Group(LCID) – The electric vehicle maker’s stock slumped 14.7% in premarket trading after it received a subpoena from the Securities and Exchange Commission. Lucid said the subpoena requested documents related to its SPAC merger deal with Churchill Capital Corp.\nTesla(TSLA) – Tesla stock dropped nearly 3% in premarket trading after the SEC launched an investigation into the informant's claim that Tesla solar panels were defective.In addition,Tesla recalled 21,599 Model Ys made in China, citing steering knuckle issues.\nAlibaba(BABA) – The China-based e-commerce giant saw its shares add 1% in premarket action after it announced a reorganization of its e-commerce teams and named a new chief financial officer.\nCF Acquisition Corp VI(CFVI) – YouTube competitor Rumble would go public via SPAC CF Acquisition VI.CF Acquisition Corp VI stock jumped 23% in premarket trading.\nDigital World Acquisition(DWAC) – Digital World Acquisition stock surged 10% in premarket trading.Trump's social media venture says it has raised $1 bln.\nKohl’s(KSS) – The retailer’s stock rallied 4.2% in the premarket following news that activist investor Engine Capital is urging Kohl’s to consider either a sale of the company or a separation of its e-commerce business. Engine Capital has a Kohl’s stake of approximately 1%.\nElectronic Arts(EA) – The video game maker gained 1.9% in premarket trading after Citi upgraded the stock to “buy” from “neutral.” Citi said the recent slide presents a buying opportunity despite concerns over factors like the weakness in EA’s “Battlefield 2042” title.\nGCP Applied Technologies(GCP) – The maker of specialty construction chemicals agreed to be acquired by French construction company Saint-Gobain for $32 per share in cash, or about $32 billion. GCP surged 14.4% in premarket trading.\nFactSet Research(FDS) – The provider of financial information will join the S&P 500 prior to the market opening on December 20, along with Signature Bank(SBNY) and SolarEdge Technologies(SEDG). They’ll replaceLeggett & Platt(LEG),Hanesbrands(HBI), and Western Union(WU), which will all move to the S&P MidCap 400.\nMicroStrategy(MSTR) – MicroStrategy tumbled 7.6% in the premarket following the weekend slide in the price of bitcoin. The business analytics software company has billions of dollars in bitcoin holdings on its balance sheet.\nSpirit Airlines(SAVE) – Spirit rose 1.4% in the premarket after Evercore upgraded the airline’s stock to “outperform” from “in-line,” saying the company winds up in a better place each time it goes through a recovery cycle.\nWells Fargo(WFC) – The bank was named a “top pick” at Morgan Stanley, which notes that faster interest rate hikes will benefit the banking sector and that the omicron Covid-19 variant will only push recovery out by a quarter or so. Wells Fargo shares added 1.4% in the premarket.\nBoston Beer(SAM) – The brewer’s stock added 1.2% in premarket action, following a Cowen upgrade to “market perform” from “underperform”. Cowen notes the slump in the stock price since August, but said it sees signs of stabilization and negative revisions to earnings are now priced into the stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1069,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821308196,"gmtCreate":1633694667882,"gmtModify":1633694668131,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Looks like mostly going up.","listText":"Looks like mostly going up.","text":"Looks like mostly going up.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/821308196","repostId":"1147933296","repostType":4,"repost":{"id":"1147933296","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633693512,"share":"https://www.laohu8.com/m/news/1147933296?lang=&edition=full","pubTime":"2021-10-08 19:45","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1147933296","media":"Tiger Newspress","summary":"(Oct 8) U.S. futures drifted and stocks edged higher as investors awaited a key employment report fo","content":"<p>(Oct&nbsp;8)&nbsp;U.S. futures drifted and stocks edged&nbsp;higher as investors awaited a key employment report for clues on the Federal Reserve’s monetary policy. Treasury yields climbed.</p>\n<p>At 7:47 a.m. ET, Dow E-minis were up 36 points, or 0.10%, S&amp;P 500 E-minis gained&nbsp;5.5 points, or 0.13% and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 E-minis rose 19.5 points, or 0.13%.</p>\n<p><img src=\"https://static.tigerbbs.com/39ee2ce0823e75ecf9646907cb0d8c53\" tg-width=\"1242\" tg-height=\"509\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Here’s what we’re watching ahead of Thursday’s open:</b></p>\n<ul>\n <li>Bitcoin rose 2.4% from its price at 5 p.m. ET on Thursday, and stocks in the crypto world were also gaining. The SEC approved Volt <a href=\"https://laohu8.com/S/EQR\">Equity</a>’s ETF, which aims to track companies that hold a majority of their assets in bitcoin or derive most of their earnings from bitcoin-related activities.Coinbasewas up 1.1% premarket, and bitcoin minerMarathon Digitalgained 2.2%.</li>\n <li><b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a> </b>shares jumped 9.7% premarket after the company said its oral Covid-19 vaccine candidate has shown it could reduce the airborne transmission of the virus in an animal model.</li>\n <li>Fellow vaccine makers&nbsp;Moderna&nbsp;and&nbsp;Novavax,&nbsp;that have suffered price stumbles recently, were also on the rise premarket, up by 0.9% and 1.6% respectively.</li>\n <li>Crude prices are climbing, and shares of energy producers are following them higher.<a href=\"https://laohu8.com/S/OXY\">Occidental</a> Petroleumadded 1.3% premarket,<a href=\"https://laohu8.com/S/DVN\">Devon</a> Energygained 1.8% and oil-services companyHalliburtonrose 1.1%.</li>\n</ul>\n<ul>\n <li><b><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a></b> shares nudged up 0.2% after the electric-car maker said it is&nbsp;moving its headquarters to Austin, Texas, adding to a handful of Silicon Valley companies that have relocated there.</li>\n <li>U.S.-traded shares of&nbsp;Chubb&nbsp;added 0.8% premarket. The Switzerland-based insurer agreed to buy some of&nbsp;Cigna‘s Asia-Pacific operations as part of its strategy to expand in the region.</li>\n <li>Accoladeshares dropped 7.3% premarket after the employee health benefits company reported a loss for the recent quarter.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-08 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct&nbsp;8)&nbsp;U.S. futures drifted and stocks edged&nbsp;higher as investors awaited a key employment report for clues on the Federal Reserve’s monetary policy. Treasury yields climbed.</p>\n<p>At 7:47 a.m. ET, Dow E-minis were up 36 points, or 0.10%, S&amp;P 500 E-minis gained&nbsp;5.5 points, or 0.13% and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 E-minis rose 19.5 points, or 0.13%.</p>\n<p><img src=\"https://static.tigerbbs.com/39ee2ce0823e75ecf9646907cb0d8c53\" tg-width=\"1242\" tg-height=\"509\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Here’s what we’re watching ahead of Thursday’s open:</b></p>\n<ul>\n <li>Bitcoin rose 2.4% from its price at 5 p.m. ET on Thursday, and stocks in the crypto world were also gaining. The SEC approved Volt <a href=\"https://laohu8.com/S/EQR\">Equity</a>’s ETF, which aims to track companies that hold a majority of their assets in bitcoin or derive most of their earnings from bitcoin-related activities.Coinbasewas up 1.1% premarket, and bitcoin minerMarathon Digitalgained 2.2%.</li>\n <li><b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a> </b>shares jumped 9.7% premarket after the company said its oral Covid-19 vaccine candidate has shown it could reduce the airborne transmission of the virus in an animal model.</li>\n <li>Fellow vaccine makers&nbsp;Moderna&nbsp;and&nbsp;Novavax,&nbsp;that have suffered price stumbles recently, were also on the rise premarket, up by 0.9% and 1.6% respectively.</li>\n <li>Crude prices are climbing, and shares of energy producers are following them higher.<a href=\"https://laohu8.com/S/OXY\">Occidental</a> Petroleumadded 1.3% premarket,<a href=\"https://laohu8.com/S/DVN\">Devon</a> Energygained 1.8% and oil-services companyHalliburtonrose 1.1%.</li>\n</ul>\n<ul>\n <li><b><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a></b> shares nudged up 0.2% after the electric-car maker said it is&nbsp;moving its headquarters to Austin, Texas, adding to a handful of Silicon Valley companies that have relocated there.</li>\n <li>U.S.-traded shares of&nbsp;Chubb&nbsp;added 0.8% premarket. The Switzerland-based insurer agreed to buy some of&nbsp;Cigna‘s Asia-Pacific operations as part of its strategy to expand in the region.</li>\n <li>Accoladeshares dropped 7.3% premarket after the employee health benefits company reported a loss for the recent quarter.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147933296","content_text":"(Oct 8) U.S. futures drifted and stocks edged higher as investors awaited a key employment report for clues on the Federal Reserve’s monetary policy. Treasury yields climbed.\nAt 7:47 a.m. ET, Dow E-minis were up 36 points, or 0.10%, S&P 500 E-minis gained 5.5 points, or 0.13% and Nasdaq 100 E-minis rose 19.5 points, or 0.13%.\n\nHere’s what we’re watching ahead of Thursday’s open:\n\nBitcoin rose 2.4% from its price at 5 p.m. ET on Thursday, and stocks in the crypto world were also gaining. The SEC approved Volt Equity’s ETF, which aims to track companies that hold a majority of their assets in bitcoin or derive most of their earnings from bitcoin-related activities.Coinbasewas up 1.1% premarket, and bitcoin minerMarathon Digitalgained 2.2%.\nVaxart, Inc shares jumped 9.7% premarket after the company said its oral Covid-19 vaccine candidate has shown it could reduce the airborne transmission of the virus in an animal model.\nFellow vaccine makers Moderna and Novavax, that have suffered price stumbles recently, were also on the rise premarket, up by 0.9% and 1.6% respectively.\nCrude prices are climbing, and shares of energy producers are following them higher.Occidental Petroleumadded 1.3% premarket,Devon Energygained 1.8% and oil-services companyHalliburtonrose 1.1%.\n\n\nTesla Motors shares nudged up 0.2% after the electric-car maker said it is moving its headquarters to Austin, Texas, adding to a handful of Silicon Valley companies that have relocated there.\nU.S.-traded shares of Chubb added 0.8% premarket. The Switzerland-based insurer agreed to buy some of Cigna‘s Asia-Pacific operations as part of its strategy to expand in the region.\nAccoladeshares dropped 7.3% premarket after the employee health benefits company reported a loss for the recent quarter.","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845641636,"gmtCreate":1636336761554,"gmtModify":1636337088742,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Doesn't seem positive sign","listText":"Doesn't seem positive sign","text":"Doesn't seem positive sign","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845641636","repostId":"2181233137","repostType":4,"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845643010,"gmtCreate":1636336663260,"gmtModify":1636337071848,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Look like an exciting week","listText":"Look like an exciting week","text":"Look like an exciting week","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845643010","repostId":"2181284457","repostType":4,"isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608167693,"gmtCreate":1638668134727,"gmtModify":1638668134860,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Maybe it's the holiday season. Stocks may he going south for vacation","listText":"Maybe it's the holiday season. Stocks may he going south for vacation","text":"Maybe it's the holiday season. Stocks may he going south for vacation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608167693","repostId":"1115344844","repostType":4,"repost":{"id":"1115344844","pubTimestamp":1638544099,"share":"https://www.laohu8.com/m/news/1115344844?lang=&edition=full","pubTime":"2021-12-03 23:08","market":"us","language":"en","title":"3 High Growth Stocks To Buy In The Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=1115344844","media":"Seeking Alpha","summary":"Summary\n\nUpstart has fallen more than 50% from its highs. But its last earnings report wasn't that b","content":"<p><b>Summary</b></p>\n<ul>\n <li>Upstart has fallen more than 50% from its highs. But its last earnings report wasn't that bad. The story is still intact and shares have derisked considerably.</li>\n <li>Zscaler continues to impress with recent results showing accelerated growth again. The shares went up immediately after the report but reversed down in the general wash out.</li>\n <li>Monday.com is a fairly new company and it also got hit by the market. Its high growth profile, rapidly improving profitability, and reasonable valuation makes it an interesting stock pick.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2aac50f1e4e4115b0d38a5ec6c15c267\" tg-width=\"1536\" tg-height=\"1139\" width=\"100%\" height=\"auto\"><span>Galeanu Mihai/iStock via Getty Images</span></p>\n<p>I started writing this article one week ago with the goal to review Upstart's recent quarterly results. Since in my&nbsp;last article, I argued that Upstart (UPST) might still be an attractive buying opportunity at $390 a share, I wanted to check on the company (currently trading around $180 –<i>yikes!</i>).</p>\n<p>However, the recent market sell-off, especially in high-growth names, made me reconsider the direction of the article. I think it is much more interesting right now to write about some high-growth names in my portfolio that I am considering adding during this little downturn.</p>\n<p>A little caveat upfront, though. I am really bad at short-term calls (as evidenced by my recent Upstart article). I have no idea what the Omicron variant will do to our economy, what the Fed's monetary policy will be in the future and how far this sell-off will go eventually. By the time this article is published, the sell-off might already have reversed. Or it might have gotten much worse. I simply don't know.</p>\n<p>What I do know is that there are companies in the public markets with exceptional business fundamentals that&nbsp;<b>will do very well regardless of the macro environment</b>. These are businesses with high growth rates, high margins, and long runways of growth. They also have high valuation multiples which lead to increased risk and high volatility. Taking advantage of that volatility is a great way to increase your returns. Here are some stocks that I consider buying right now:</p>\n<p><b>Upstart</b></p>\n<p>Let's start with the one I originally wanted to write about: To summarize shortly, I think that if you liked Upstart at $390, you should like it much more at $180. The earnings release for Q3 2021 was not as bad as the market's reaction might suggest. Yes, expectations were lofty based on an exceptional Q2 report, and yes, these expectations were not entirely met in Q3. But that does not mean that the fundamental picture has deteriorated. What the wild price swings of the past prove, and I have written about in the past, is that this young company is difficult to value. Growth is high, but also hard to predict. And while the disruption of the FICO score through AI technology is enticing and seems inevitable, Upstart's role in that story is not set in stone.</p>\n<p>Let's look at some numbers:</p>\n<p><img src=\"https://static.tigerbbs.com/7b085c5134a9e376f177da8f5fa2674e\" tg-width=\"640\" tg-height=\"309\" width=\"100%\" height=\"auto\"></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b826680751b139c569c90d0d3be483cf\" tg-width=\"640\" tg-height=\"163\" width=\"100%\" height=\"auto\"><span>Source: Author</span></p>\n<p>As you can see, revenue growth is still explosive, and with a normal beat should accelerate again into Q4 on a sequential basis. And while most key performance indicators (loans transacted, conversion rate, percentage of automated loans) together with&nbsp;margins&nbsp;all decelerated or went down slightly, I don't think that this means the fundamentals have changed with this company. There were many details mentioned in the&nbsp;earnings call&nbsp;that I won't discuss in this article format. But the key takeaway for me was that management seemed very upbeat about the future of the company.</p>\n<p>I think there are two key mistakes that investors should avoid here:</p>\n<ol>\n <li>Let the disappointment of a \"not-so-blowout\" quarter and a devastating price action make you blind to this investment opportunity. This was still a very good quarter and now that the shares have fallen off a cliff the stock is much more attractive.</li>\n <li>Do not look at Upstart through the lens of SaaS businesses. As I wrote in&nbsp;May:<i>Upstart might be a high-promising cloud software company but it does not have a SaaS business model. There is</i>&nbsp;<i><b>no recurring revenue</b></i>&nbsp;<i>to fall back on in tough times, no sticky subscription customers, no backlog, no land and expand. Every quarter Upstart has to sell new loans, and revenue basically starts from zero.</i></li>\n</ol>\n<p>Upstart's financials are lumpier and less reliable and as a result, the company deserves much more investor attention and a lower valuation multiple than high growth companies with recurring revenues. However, if growth stays very high, it could more than make up for that fact. Currently, the company is trading at a 17.76 forward EV/S, which I think is a relative bargain for a company with this growth and margin profile.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/15592919228dec8ee2403898d69ef228\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><b>Zscaler</b></p>\n<p>Sometimes the market gives you a gift that you should not refuse. This is what happened with Zscaler (ZS) yesterday. The&nbsp;stock initially was up&nbsp;in the postmarket after the company reported another&nbsp;blow-out quarter&nbsp;on Tuesday. But on Wednesday it all didn't matter anymore and thanks to the little correction, sector rotation, or whatever you want to call it, the stock actually went&nbsp;<b>down by more than 8%</b>. This is really a time when you want to buy: You just got confirmation that your company is doing incredibly well with growth accelerating and the stock sells off for macro concerns. The stock is definitely not cheap at a forward EV/S of 43.51 and, of course, this \"pull-back\" is laughable (<i>\"oh my god, the stock is back to where it was...one month ago\"</i>).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e79ff3fce3101896f17b65ced143c037\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p>But I like to own companies that are doing exceptional things and I don't mind paying up for them, especially in a turbulent market.</p>\n<p>How exceptional is Zscaler? Just look at those revenue growth numbers:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3def4410c8c903a03041a2cd51b36979\" tg-width=\"640\" tg-height=\"386\" width=\"100%\" height=\"auto\"><span>Source: Author.</span></p>\n<p>I&nbsp;thought&nbsp;in May that growth acceleration might end soon, but it has continued to accelerate in Q1 2022. If the company beats its guidance in Q2 in a similar fashion to the past (usually more than 5%), it should accelerate year-on-year growth again in Q2 (or at least maintain the current 60%+ growth rate). On top of that, this quarter saw&nbsp;<b>RPO growing 98%, a dollar-based net retention rate of 125%, and FCF margins of 36%</b>. In other words, this business is firing on all cylinders. If you don't know what Zscaler does,read my article from December 2018&nbsp;– the stock is up 710% since then, and I think it can go even higher.</p>\n<p><b>Monday.com</b></p>\n<p>Monday.com (MNDY) is a company that is a relatively new stock in the public markets (it IPOed in June this year) and a completely new stock in my portfolio (I just bought my first position). In a nutshell, the reason why I bought Monday.com is their hyper-growth and rapidly improving profitability. Just look at these two slides from the most recent earnings call presentation:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c5b07658237c02685eb3d049a537ba61\" tg-width=\"640\" tg-height=\"727\" width=\"100%\" height=\"auto\"><span>Source: Earnings call presentation Q3 2021.</span></p>\n<p>Revenue was&nbsp;<b>up 95%</b>(up from 94% in the last quarter). This is quite astounding growth which indicates that this company is winning in the market (but also consider that the company is at a small annual revenue run rate, which makes it a bit easier). The number of enterprise customerswith more than $50K ARRwas&nbsp;<b>up 231%</b>(at 613, up from 185 a year ago). Monday was also&nbsp;<b>cash flow positive</b>&nbsp;for the first time this quarter.</p>\n<p>On top of that, it is also cheap relative to other cloud stocks:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80e6afbf54bdde4ad31dd3aaa06d0073\" tg-width=\"640\" tg-height=\"368\" width=\"100%\" height=\"auto\"><span>Source: Clouded Judgement 11.26.21.</span></p>\n<p>The company currently has a TTM EV/S of 57, and a 2022 EV/S of 38.7, based on analysts' expectation of 47% growth in 2022. That seems rich but not terribly so relative to other cloud names. The growth expectation of 47% in 2022, however, seems quite low if you consider the current growth of 95% year-on-year and 17% sequentially, plus the current momentum in larger customers. Actually, anything below 70% growth in FY 2022 would come as a surprise to me, and then we are looking at a maximum forward EV/S of 33.</p>\n<p>The big question going forward – in terms of if Monday.com will be a good long-term investment – is to which extent Monday.com can maintain its high growth rate beyond FY 2022. Here I do have some doubts still. The company is operating in a very dynamic and competitive field and I am not yet sure where Monday differentiates itself meaningfully from companies like Asana (ASAN) or Atlassian (TEAM). Still, the market for cloud-based work management solutions is big and there can be many winners in the space. For the moment I'm happy to follow the numbers (which look fantastic) and hope that the relatively cheap valuation will result in substantial alpha and is not an indication of a lower quality company.</p>\n<p><b>Closing Thoughts And Honorary Mentions</b></p>\n<p>On days like these, there are many companies worth considering. For example, I haven't mentioned Datadog (DDOG) which&nbsp;reported another fantastic quarter&nbsp;at the beginning of November. Like Zscaler, this is also a company with accelerating growth that you can buy at a lower price than it was before it reported its blowout results.</p>\n<p>Remember that the stocks mentioned, even though they may look attractive from a relative perspective, are still very expensive in absolute terms and from a historical perspective. However, sustainable growth is a beautiful form of downside protection for investors and the best antidote to \"overvaluation\" that I know. If I learned one thing in the last four years investing in high-growth SaaS/cloud stocks, it is to stay invested in the companies that sustain (or preferably accelerate) their top-line growth and get out of the stocks that see slowdowns. That sounds terribly simplistic and of course, many other factors play a role in a stock's long-term gains, but revenue growth and its&nbsp;endurance&nbsp;have been the predominant factors in the past.</p>\n<p>This pull-back is far from the worst I have seen in recent years. But it is still painful – and when it starts to hurt, it is usually a good time to buy some quality companies.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 High Growth Stocks To Buy In The Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 High Growth Stocks To Buy In The Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 23:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4473014-3-high-growth-stocks-to-buy-in-the-pullback><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nUpstart has fallen more than 50% from its highs. But its last earnings report wasn't that bad. The story is still intact and shares have derisked considerably.\nZscaler continues to impress ...</p>\n\n<a href=\"https://seekingalpha.com/article/4473014-3-high-growth-stocks-to-buy-in-the-pullback\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UPST":"Upstart Holdings, Inc.","ZS":"Zscaler Inc.","MNDY":"Monday.com Ltd."},"source_url":"https://seekingalpha.com/article/4473014-3-high-growth-stocks-to-buy-in-the-pullback","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115344844","content_text":"Summary\n\nUpstart has fallen more than 50% from its highs. But its last earnings report wasn't that bad. The story is still intact and shares have derisked considerably.\nZscaler continues to impress with recent results showing accelerated growth again. The shares went up immediately after the report but reversed down in the general wash out.\nMonday.com is a fairly new company and it also got hit by the market. Its high growth profile, rapidly improving profitability, and reasonable valuation makes it an interesting stock pick.\n\nGaleanu Mihai/iStock via Getty Images\nI started writing this article one week ago with the goal to review Upstart's recent quarterly results. Since in my last article, I argued that Upstart (UPST) might still be an attractive buying opportunity at $390 a share, I wanted to check on the company (currently trading around $180 –yikes!).\nHowever, the recent market sell-off, especially in high-growth names, made me reconsider the direction of the article. I think it is much more interesting right now to write about some high-growth names in my portfolio that I am considering adding during this little downturn.\nA little caveat upfront, though. I am really bad at short-term calls (as evidenced by my recent Upstart article). I have no idea what the Omicron variant will do to our economy, what the Fed's monetary policy will be in the future and how far this sell-off will go eventually. By the time this article is published, the sell-off might already have reversed. Or it might have gotten much worse. I simply don't know.\nWhat I do know is that there are companies in the public markets with exceptional business fundamentals that will do very well regardless of the macro environment. These are businesses with high growth rates, high margins, and long runways of growth. They also have high valuation multiples which lead to increased risk and high volatility. Taking advantage of that volatility is a great way to increase your returns. Here are some stocks that I consider buying right now:\nUpstart\nLet's start with the one I originally wanted to write about: To summarize shortly, I think that if you liked Upstart at $390, you should like it much more at $180. The earnings release for Q3 2021 was not as bad as the market's reaction might suggest. Yes, expectations were lofty based on an exceptional Q2 report, and yes, these expectations were not entirely met in Q3. But that does not mean that the fundamental picture has deteriorated. What the wild price swings of the past prove, and I have written about in the past, is that this young company is difficult to value. Growth is high, but also hard to predict. And while the disruption of the FICO score through AI technology is enticing and seems inevitable, Upstart's role in that story is not set in stone.\nLet's look at some numbers:\n\nSource: Author\nAs you can see, revenue growth is still explosive, and with a normal beat should accelerate again into Q4 on a sequential basis. And while most key performance indicators (loans transacted, conversion rate, percentage of automated loans) together with margins all decelerated or went down slightly, I don't think that this means the fundamentals have changed with this company. There were many details mentioned in the earnings call that I won't discuss in this article format. But the key takeaway for me was that management seemed very upbeat about the future of the company.\nI think there are two key mistakes that investors should avoid here:\n\nLet the disappointment of a \"not-so-blowout\" quarter and a devastating price action make you blind to this investment opportunity. This was still a very good quarter and now that the shares have fallen off a cliff the stock is much more attractive.\nDo not look at Upstart through the lens of SaaS businesses. As I wrote in May:Upstart might be a high-promising cloud software company but it does not have a SaaS business model. There is no recurring revenue to fall back on in tough times, no sticky subscription customers, no backlog, no land and expand. Every quarter Upstart has to sell new loans, and revenue basically starts from zero.\n\nUpstart's financials are lumpier and less reliable and as a result, the company deserves much more investor attention and a lower valuation multiple than high growth companies with recurring revenues. However, if growth stays very high, it could more than make up for that fact. Currently, the company is trading at a 17.76 forward EV/S, which I think is a relative bargain for a company with this growth and margin profile.\nData by YCharts\nZscaler\nSometimes the market gives you a gift that you should not refuse. This is what happened with Zscaler (ZS) yesterday. The stock initially was up in the postmarket after the company reported another blow-out quarter on Tuesday. But on Wednesday it all didn't matter anymore and thanks to the little correction, sector rotation, or whatever you want to call it, the stock actually went down by more than 8%. This is really a time when you want to buy: You just got confirmation that your company is doing incredibly well with growth accelerating and the stock sells off for macro concerns. The stock is definitely not cheap at a forward EV/S of 43.51 and, of course, this \"pull-back\" is laughable (\"oh my god, the stock is back to where it was...one month ago\").\nData by YCharts\nBut I like to own companies that are doing exceptional things and I don't mind paying up for them, especially in a turbulent market.\nHow exceptional is Zscaler? Just look at those revenue growth numbers:\nSource: Author.\nI thought in May that growth acceleration might end soon, but it has continued to accelerate in Q1 2022. If the company beats its guidance in Q2 in a similar fashion to the past (usually more than 5%), it should accelerate year-on-year growth again in Q2 (or at least maintain the current 60%+ growth rate). On top of that, this quarter saw RPO growing 98%, a dollar-based net retention rate of 125%, and FCF margins of 36%. In other words, this business is firing on all cylinders. If you don't know what Zscaler does,read my article from December 2018 – the stock is up 710% since then, and I think it can go even higher.\nMonday.com\nMonday.com (MNDY) is a company that is a relatively new stock in the public markets (it IPOed in June this year) and a completely new stock in my portfolio (I just bought my first position). In a nutshell, the reason why I bought Monday.com is their hyper-growth and rapidly improving profitability. Just look at these two slides from the most recent earnings call presentation:\nSource: Earnings call presentation Q3 2021.\nRevenue was up 95%(up from 94% in the last quarter). This is quite astounding growth which indicates that this company is winning in the market (but also consider that the company is at a small annual revenue run rate, which makes it a bit easier). The number of enterprise customerswith more than $50K ARRwas up 231%(at 613, up from 185 a year ago). Monday was also cash flow positive for the first time this quarter.\nOn top of that, it is also cheap relative to other cloud stocks:\nSource: Clouded Judgement 11.26.21.\nThe company currently has a TTM EV/S of 57, and a 2022 EV/S of 38.7, based on analysts' expectation of 47% growth in 2022. That seems rich but not terribly so relative to other cloud names. The growth expectation of 47% in 2022, however, seems quite low if you consider the current growth of 95% year-on-year and 17% sequentially, plus the current momentum in larger customers. Actually, anything below 70% growth in FY 2022 would come as a surprise to me, and then we are looking at a maximum forward EV/S of 33.\nThe big question going forward – in terms of if Monday.com will be a good long-term investment – is to which extent Monday.com can maintain its high growth rate beyond FY 2022. Here I do have some doubts still. The company is operating in a very dynamic and competitive field and I am not yet sure where Monday differentiates itself meaningfully from companies like Asana (ASAN) or Atlassian (TEAM). Still, the market for cloud-based work management solutions is big and there can be many winners in the space. For the moment I'm happy to follow the numbers (which look fantastic) and hope that the relatively cheap valuation will result in substantial alpha and is not an indication of a lower quality company.\nClosing Thoughts And Honorary Mentions\nOn days like these, there are many companies worth considering. For example, I haven't mentioned Datadog (DDOG) which reported another fantastic quarter at the beginning of November. Like Zscaler, this is also a company with accelerating growth that you can buy at a lower price than it was before it reported its blowout results.\nRemember that the stocks mentioned, even though they may look attractive from a relative perspective, are still very expensive in absolute terms and from a historical perspective. However, sustainable growth is a beautiful form of downside protection for investors and the best antidote to \"overvaluation\" that I know. If I learned one thing in the last four years investing in high-growth SaaS/cloud stocks, it is to stay invested in the companies that sustain (or preferably accelerate) their top-line growth and get out of the stocks that see slowdowns. That sounds terribly simplistic and of course, many other factors play a role in a stock's long-term gains, but revenue growth and its endurance have been the predominant factors in the past.\nThis pull-back is far from the worst I have seen in recent years. But it is still painful – and when it starts to hurt, it is usually a good time to buy some quality companies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855176855,"gmtCreate":1635346038695,"gmtModify":1635346149970,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Seem like a confident stock.&nbsp;","listText":"Seem like a confident stock.&nbsp;","text":"Seem like a confident stock.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/855176855","repostId":"1106140847","repostType":4,"repost":{"id":"1106140847","pubTimestamp":1635343863,"share":"https://www.laohu8.com/m/news/1106140847?lang=&edition=full","pubTime":"2021-10-27 22:11","market":"us","language":"en","title":"Brazil's Nubank, last valued at $30 billion, confidentially files for U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1106140847","media":"Reuters","summary":"(Reuters) - Brazilian digital lender Nubank, which is backed by Warren Buffett’s Berkshire Hathaway ","content":"<p>(Reuters) - Brazilian digital lender Nubank, which is backed by Warren Buffett’s Berkshire Hathaway Inc, said on Wednesday it had confidentially filed for an initial public offering in the United States.</p>\n<p>The market debut of the Sao Paulo-based company, valued at $30 billion after a Berkshire-led investment in June, is expected to be one of the biggest IPOs of a South American company in recent years.</p>\n<p>Nubank could seek a valuation of more than $55 billion, Reuters reported in August&nbsp;here.</p>\n<p>Perks including no fees or minimum balance requirements have added to the appeal of lenders such as Nubank. The trend has only accelerated during the pandemic that forced people to turn to mobile phone apps for banking solutions.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brazil's Nubank, last valued at $30 billion, confidentially files for U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrazil's Nubank, last valued at $30 billion, confidentially files for U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-27 22:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/nubank-ipo/update-2-brazils-nubank-last-valued-at-30-bln-confidentially-files-for-u-s-ipo-idUSL4N2RN44Q><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Brazilian digital lender Nubank, which is backed by Warren Buffett’s Berkshire Hathaway Inc, said on Wednesday it had confidentially filed for an initial public offering in the United ...</p>\n\n<a href=\"https://www.reuters.com/article/nubank-ipo/update-2-brazils-nubank-last-valued-at-30-bln-confidentially-files-for-u-s-ipo-idUSL4N2RN44Q\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.reuters.com/article/nubank-ipo/update-2-brazils-nubank-last-valued-at-30-bln-confidentially-files-for-u-s-ipo-idUSL4N2RN44Q","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106140847","content_text":"(Reuters) - Brazilian digital lender Nubank, which is backed by Warren Buffett’s Berkshire Hathaway Inc, said on Wednesday it had confidentially filed for an initial public offering in the United States.\nThe market debut of the Sao Paulo-based company, valued at $30 billion after a Berkshire-led investment in June, is expected to be one of the biggest IPOs of a South American company in recent years.\nNubank could seek a valuation of more than $55 billion, Reuters reported in August here.\nPerks including no fees or minimum balance requirements have added to the appeal of lenders such as Nubank. The trend has only accelerated during the pandemic that forced people to turn to mobile phone apps for banking solutions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608164742,"gmtCreate":1638668011612,"gmtModify":1638668011716,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Marvell- superhero company? Like Nvidia, need to monitor&nbsp;","listText":"Marvell- superhero company? Like Nvidia, need to monitor&nbsp;","text":"Marvell- superhero company? Like Nvidia, need to monitor","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608164742","repostId":"2188787815","repostType":4,"repost":{"id":"2188787815","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638583020,"share":"https://www.laohu8.com/m/news/2188787815?lang=&edition=full","pubTime":"2021-12-04 09:57","market":"us","language":"en","title":"Marvell will be 'in the same camp' as AMD, Nvidia after 'one of the best' semiconductor earnings calls","url":"https://stock-news.laohu8.com/highlight/detail?id=2188787815","media":"Dow Jones","summary":"Stock jumps more than 17%, its best day since 2008, as analysts describe chip maker's earnings as 'w","content":"<p>Stock jumps more than 17%, its best day since 2008, as analysts describe chip maker's earnings as 'watershed quarter'</p>\n<p>Shares of Marvell Technology Inc. experienced their best trading day in 13 years after an earnings report that led analysts to predict the chip maker's ascension into the top tier of hot semiconductor stocks.</p>\n<p>Marvell shares <a href=\"https://laohu8.com/S/MRVL\">$(MRVL)$</a> increased 17.7% Friday following the company's fiscal third-quarter earnings report, which saw Marvell top expectations for its latest quarter, issue an upbeat forecast for the current period, and offer encouraging longer-term commentary. The stock posted its largest single-day percentage gain since Dec. 3, 2008, when it rose 20.4%.</p>\n<p>Chief Financial Officer Jean Hu said on the earnings call late Thursday that she expects \"continued strong demand across our end markets and improvement in supply to drive our top line revenue growth above 30% in fiscal 2023.\" That projection generated enthusiasm, as did Marvell's January-quarter revenue forecast that implied upwards of 60% growth.</p>\n<p>The company's earnings call could have been \"one of the best (if not the best) semi conf[erence] calls I have listened to in quite some time,\" wrote Mizuho desk-based analyst Jordan Klein in a note affiliated with Mizuho's sales operations and not its research team. \"In fact, it was a GAME-CHANGER for investors and in my view squarely positions Marvell as a best-in-class GROWTH SEMI into CY22,\" he continued.</p>\n<p>Marvell \"will be in the same camp now\" as Advanced Micro Devices Inc. <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a> and Nvidia Corp. <a href=\"https://laohu8.com/S/NVDA\">$(NVDA)$</a>, he argued, amid the company's cheery growth projections and likely expectations among the bull camp for $4 a share in annual earnings power within a few years. The company has a \"clear line of sight given a backlog full of design wins that has basically locked in that growth rate\" on the revenue line, he said in his note.</p>\n<p>The current FactSet EPS consensus is $1.54 for the current fiscal year, and is $2.20 for next year.</p>\n<p>Klein wasn't alone in likening Marvell to a red-hot chip stock. \"Marvell just pulled an 'Nvidia' on the Street last night, with an unambiguous beat and raise and taking FY23 sales growth to over 30%,\" Rosenblatt Securities analyst Hans Mosesmann wrote.</p>\n<p>Marvell's report sparked at least one upgrade from a research analyst: Cowen &amp; Co.'s Karl Ackerman, who lifted his rating on Marvell's stock to outperform from market perform.</p>\n<p>\"It's hard to argue this was anything but a watershed quarter with a triad of better results, better guidance, and an expanding design pipeline that anchors a new F23 guide,\" Ackerman wrote.</p>\n<p>Ackerman cheered Marvell's recent evolution, anchored by \"portfolio-optimization\" progress that has made the company increasingly competitive, in his view.</p>\n<p>\"Marvell has transformed itself from being a fast-follower to a market leader of providing semi-custom, integrated ICs on leading-edge silicon that address bandwidth friction existing in today's networks,\" he wrote, while increasing his price target to $100 from $60.</p>\n<p>The report served as validation for those who had already taken bullish views on the stock and are now bringing their expectations higher. \"Taking a step back, we have been highlighting Marvell as one of the best growth stories in semis, and to this end they are clearly not disappointing,\" Evercore ISI analyst C.J. Muse wrote.</p>\n<p>Muse now sees \"a clear path to a $3.25+ earnings stretch goal in FY24,\" whereas the consensus was for $2.43 a share, he said. \"Looking out further, we believe that the $4.00 bogey we have been discussing by CY25 is now likely conservative -- with earnings likely tracking closer to $4.25+ when all is said and done (at a minimum),\" Muse continued, while boosting his price target to $105 from $72 and keeping an outperform rating.</p>\n<p>Marvell shares have rocketed 75% so far this year, while Nvidia shares have soared 134%, AMD's stock has rallied 56% and the S&amp;P 500 has risen 20%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marvell will be 'in the same camp' as AMD, Nvidia after 'one of the best' semiconductor earnings calls</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarvell will be 'in the same camp' as AMD, Nvidia after 'one of the best' semiconductor earnings calls\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-04 09:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stock jumps more than 17%, its best day since 2008, as analysts describe chip maker's earnings as 'watershed quarter'</p>\n<p>Shares of Marvell Technology Inc. experienced their best trading day in 13 years after an earnings report that led analysts to predict the chip maker's ascension into the top tier of hot semiconductor stocks.</p>\n<p>Marvell shares <a href=\"https://laohu8.com/S/MRVL\">$(MRVL)$</a> increased 17.7% Friday following the company's fiscal third-quarter earnings report, which saw Marvell top expectations for its latest quarter, issue an upbeat forecast for the current period, and offer encouraging longer-term commentary. The stock posted its largest single-day percentage gain since Dec. 3, 2008, when it rose 20.4%.</p>\n<p>Chief Financial Officer Jean Hu said on the earnings call late Thursday that she expects \"continued strong demand across our end markets and improvement in supply to drive our top line revenue growth above 30% in fiscal 2023.\" That projection generated enthusiasm, as did Marvell's January-quarter revenue forecast that implied upwards of 60% growth.</p>\n<p>The company's earnings call could have been \"one of the best (if not the best) semi conf[erence] calls I have listened to in quite some time,\" wrote Mizuho desk-based analyst Jordan Klein in a note affiliated with Mizuho's sales operations and not its research team. \"In fact, it was a GAME-CHANGER for investors and in my view squarely positions Marvell as a best-in-class GROWTH SEMI into CY22,\" he continued.</p>\n<p>Marvell \"will be in the same camp now\" as Advanced Micro Devices Inc. <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a> and Nvidia Corp. <a href=\"https://laohu8.com/S/NVDA\">$(NVDA)$</a>, he argued, amid the company's cheery growth projections and likely expectations among the bull camp for $4 a share in annual earnings power within a few years. The company has a \"clear line of sight given a backlog full of design wins that has basically locked in that growth rate\" on the revenue line, he said in his note.</p>\n<p>The current FactSet EPS consensus is $1.54 for the current fiscal year, and is $2.20 for next year.</p>\n<p>Klein wasn't alone in likening Marvell to a red-hot chip stock. \"Marvell just pulled an 'Nvidia' on the Street last night, with an unambiguous beat and raise and taking FY23 sales growth to over 30%,\" Rosenblatt Securities analyst Hans Mosesmann wrote.</p>\n<p>Marvell's report sparked at least one upgrade from a research analyst: Cowen &amp; Co.'s Karl Ackerman, who lifted his rating on Marvell's stock to outperform from market perform.</p>\n<p>\"It's hard to argue this was anything but a watershed quarter with a triad of better results, better guidance, and an expanding design pipeline that anchors a new F23 guide,\" Ackerman wrote.</p>\n<p>Ackerman cheered Marvell's recent evolution, anchored by \"portfolio-optimization\" progress that has made the company increasingly competitive, in his view.</p>\n<p>\"Marvell has transformed itself from being a fast-follower to a market leader of providing semi-custom, integrated ICs on leading-edge silicon that address bandwidth friction existing in today's networks,\" he wrote, while increasing his price target to $100 from $60.</p>\n<p>The report served as validation for those who had already taken bullish views on the stock and are now bringing their expectations higher. \"Taking a step back, we have been highlighting Marvell as one of the best growth stories in semis, and to this end they are clearly not disappointing,\" Evercore ISI analyst C.J. Muse wrote.</p>\n<p>Muse now sees \"a clear path to a $3.25+ earnings stretch goal in FY24,\" whereas the consensus was for $2.43 a share, he said. \"Looking out further, we believe that the $4.00 bogey we have been discussing by CY25 is now likely conservative -- with earnings likely tracking closer to $4.25+ when all is said and done (at a minimum),\" Muse continued, while boosting his price target to $105 from $72 and keeping an outperform rating.</p>\n<p>Marvell shares have rocketed 75% so far this year, while Nvidia shares have soared 134%, AMD's stock has rallied 56% and the S&amp;P 500 has risen 20%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","MRVL":"迈威尔科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188787815","content_text":"Stock jumps more than 17%, its best day since 2008, as analysts describe chip maker's earnings as 'watershed quarter'\nShares of Marvell Technology Inc. experienced their best trading day in 13 years after an earnings report that led analysts to predict the chip maker's ascension into the top tier of hot semiconductor stocks.\nMarvell shares $(MRVL)$ increased 17.7% Friday following the company's fiscal third-quarter earnings report, which saw Marvell top expectations for its latest quarter, issue an upbeat forecast for the current period, and offer encouraging longer-term commentary. The stock posted its largest single-day percentage gain since Dec. 3, 2008, when it rose 20.4%.\nChief Financial Officer Jean Hu said on the earnings call late Thursday that she expects \"continued strong demand across our end markets and improvement in supply to drive our top line revenue growth above 30% in fiscal 2023.\" That projection generated enthusiasm, as did Marvell's January-quarter revenue forecast that implied upwards of 60% growth.\nThe company's earnings call could have been \"one of the best (if not the best) semi conf[erence] calls I have listened to in quite some time,\" wrote Mizuho desk-based analyst Jordan Klein in a note affiliated with Mizuho's sales operations and not its research team. \"In fact, it was a GAME-CHANGER for investors and in my view squarely positions Marvell as a best-in-class GROWTH SEMI into CY22,\" he continued.\nMarvell \"will be in the same camp now\" as Advanced Micro Devices Inc. $(AMD)$ and Nvidia Corp. $(NVDA)$, he argued, amid the company's cheery growth projections and likely expectations among the bull camp for $4 a share in annual earnings power within a few years. The company has a \"clear line of sight given a backlog full of design wins that has basically locked in that growth rate\" on the revenue line, he said in his note.\nThe current FactSet EPS consensus is $1.54 for the current fiscal year, and is $2.20 for next year.\nKlein wasn't alone in likening Marvell to a red-hot chip stock. \"Marvell just pulled an 'Nvidia' on the Street last night, with an unambiguous beat and raise and taking FY23 sales growth to over 30%,\" Rosenblatt Securities analyst Hans Mosesmann wrote.\nMarvell's report sparked at least one upgrade from a research analyst: Cowen & Co.'s Karl Ackerman, who lifted his rating on Marvell's stock to outperform from market perform.\n\"It's hard to argue this was anything but a watershed quarter with a triad of better results, better guidance, and an expanding design pipeline that anchors a new F23 guide,\" Ackerman wrote.\nAckerman cheered Marvell's recent evolution, anchored by \"portfolio-optimization\" progress that has made the company increasingly competitive, in his view.\n\"Marvell has transformed itself from being a fast-follower to a market leader of providing semi-custom, integrated ICs on leading-edge silicon that address bandwidth friction existing in today's networks,\" he wrote, while increasing his price target to $100 from $60.\nThe report served as validation for those who had already taken bullish views on the stock and are now bringing their expectations higher. \"Taking a step back, we have been highlighting Marvell as one of the best growth stories in semis, and to this end they are clearly not disappointing,\" Evercore ISI analyst C.J. Muse wrote.\nMuse now sees \"a clear path to a $3.25+ earnings stretch goal in FY24,\" whereas the consensus was for $2.43 a share, he said. \"Looking out further, we believe that the $4.00 bogey we have been discussing by CY25 is now likely conservative -- with earnings likely tracking closer to $4.25+ when all is said and done (at a minimum),\" Muse continued, while boosting his price target to $105 from $72 and keeping an outperform rating.\nMarvell shares have rocketed 75% so far this year, while Nvidia shares have soared 134%, AMD's stock has rallied 56% and the S&P 500 has risen 20%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1013,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879250947,"gmtCreate":1636729609420,"gmtModify":1636732552491,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Easy treatment for Covid-19 👍","listText":"Easy treatment for Covid-19 👍","text":"Easy treatment for Covid-19 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879250947","repostId":"1148576456","repostType":2,"repost":{"id":"1148576456","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636728443,"share":"https://www.laohu8.com/m/news/1148576456?lang=&edition=full","pubTime":"2021-11-12 22:47","market":"us","language":"en","title":"Altamira Therapeutics soared nearly 100% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1148576456","media":"Tiger Newspress","summary":"Altamira Therapeutics soared nearly 100% in morning trading.Altamira Therapeutics Ltd., a company de","content":"<p>Altamira&nbsp;Therapeutics&nbsp;soared&nbsp;nearly&nbsp;100%&nbsp;in&nbsp;morning&nbsp;trading.<img src=\"https://static.tigerbbs.com/f18f319e1b206770d5639548e9a07877\" tg-width=\"881\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Altamira Therapeutics Ltd., a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today positive efficacy data from testing its Bentrio™ nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus.</p>\n<p>Bentrio™ is a drug-free nasal spray for protection against airborne viruses and allergens, which has previously shown positive outcomes in a test against the Alpha variant of the virus.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altamira Therapeutics soared nearly 100% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltamira Therapeutics soared nearly 100% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-12 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Altamira&nbsp;Therapeutics&nbsp;soared&nbsp;nearly&nbsp;100%&nbsp;in&nbsp;morning&nbsp;trading.<img src=\"https://static.tigerbbs.com/f18f319e1b206770d5639548e9a07877\" tg-width=\"881\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Altamira Therapeutics Ltd., a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today positive efficacy data from testing its Bentrio™ nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus.</p>\n<p>Bentrio™ is a drug-free nasal spray for protection against airborne viruses and allergens, which has previously shown positive outcomes in a test against the Alpha variant of the virus.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CYTO":"Altamira Therapeutics Ltd."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148576456","content_text":"Altamira Therapeutics soared nearly 100% in morning trading.Altamira Therapeutics Ltd., a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today positive efficacy data from testing its Bentrio™ nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus.\nBentrio™ is a drug-free nasal spray for protection against airborne viruses and allergens, which has previously shown positive outcomes in a test against the Alpha variant of the virus.","news_type":1},"isVote":1,"tweetType":1,"viewCount":661,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825913447,"gmtCreate":1634188594828,"gmtModify":1634188594904,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good to monitor","listText":"Good to monitor","text":"Good to monitor","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825913447","repostId":"2175503591","repostType":4,"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846686643,"gmtCreate":1636077977968,"gmtModify":1636079490224,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"AIG coming back strongly&nbsp;","listText":"AIG coming back strongly&nbsp;","text":"AIG coming back strongly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846686643","repostId":"2181797266","repostType":4,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825919513,"gmtCreate":1634188502287,"gmtModify":1634188502361,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Selling mode??","listText":"Selling mode??","text":"Selling mode??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825919513","repostId":"1100517973","repostType":4,"isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820061547,"gmtCreate":1633326597666,"gmtModify":1633326752481,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Flying may be open. Unless real urgent and necessary, would be on wait-see mentality as still unsure if any sudden closure or quarantine measure.&nbsp;","listText":"Flying may be open. Unless real urgent and necessary, would be on wait-see mentality as still unsure if any sudden closure or quarantine measure.&nbsp;","text":"Flying may be open. Unless real urgent and necessary, would be on wait-see mentality as still unsure if any sudden closure or quarantine measure.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820061547","repostId":"2172202963","repostType":4,"isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846682292,"gmtCreate":1636078065172,"gmtModify":1636079495059,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hopefully the pill is effective&nbsp;","listText":"Hopefully the pill is effective&nbsp;","text":"Hopefully the pill is effective","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846682292","repostId":"2180795475","repostType":4,"isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":828462928,"gmtCreate":1633937343439,"gmtModify":1633937748581,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hopefully an effective drug for treating Covid.","listText":"Hopefully an effective drug for treating Covid.","text":"Hopefully an effective drug for treating Covid.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/828462928","repostId":"1184886071","repostType":4,"isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865386635,"gmtCreate":1632954198567,"gmtModify":1632954198777,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Positive or negative? Hopeful","listText":"Positive or negative? Hopeful","text":"Positive or negative? Hopeful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865386635","repostId":"2171980870","repostType":4,"isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}